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Basal-like breast cancer (BLBC) and luminal breast cancer are two major subtypes of 
breast cancer and BLBC represent the more aggressive subtype compared to luminal breast 
cancer. This observation is associated with higher expression of EZH2 and constitutive 
activation of NF-κB pathway in BLBC. In this study, we sought to dissect the crosstalk 
between EZH2 and NF-κB under these two cellular contexts. 
From our genome-wide mRNA expression profiling in a BLBC cell line, MDA-MB-
231, EZH2 was found to positively modulate NF-κB-mediated inflammatory responses. This 
relationship was validated by a series of cell-based assays. We examined the DNA 
recruitment of EZH2 and NF-κB on the promoter of NF-κB target genes as well as the 
changes of the target genes expression. EZH2 was found to exert a positive role in regulating 
DNA binding activity of RelA and RelB, and accordingly upregulate the expression levels of 
NF-κB target genes. Using co-immunoprecipitation and in vitro pull down assay, we 
demonstrated that EZH2 could physically interact with RelA and RelB forming a ternary 
complex. These interactions did not require SET domain of EZH2, suggesting a novel 
function of EZH2 independent of its SET-dependent histone methylation activity. 
The importance of this crosstalk was further demonstrated by analyzing 
EZH2/RelA/RelB coregulated genes in terms of their association with metastases in different 
breast cancer subtypes. Strikingly, there was a set of 12 genes, which were consistently 
expressed higher in BLBC or ER-negative breast cancer tissues and showed significant 
association with lung and brain metastases. This outcome revealed a potential role of 
EZH2/RelA/RelB crosstalk in promoting invasion and metastasis of aggressive breast cancer. 
Unlike ER-negative BLBC cells, ER-positive luminal breast cancer cells showed 
reduced level of RelB and concurrently exhibit high level of ER as well as its cofactors such 
as FOXA1 and GATA3. Under this cellular context, EZH2 was found to function as a 





dependent on the canonical H3K27 trimethylation activity of EZH2, potentially recruited by 
ER to the promoter of NF-κB target genes IL8 and IL6. Interestingly, the ectopic 
overexpression of RelB in ER-positive luminal breast cancer cell line, MCF7, could partially 
revert the function of EZH2 to become the transactivator of NF-κB target gene, IL6. These 
observations suggest that the presence of RelB and ER as possible crucial determinants of the 
functionality of EZH2 in regulating NF-κB gene network.  
Taken together, this study proposed a model highlighting a dual-function of EZH2 in 
modulating NF-κB network depending on cellular context. Importantly, the balance of ER 
and RelB expression could possibly be the major factors in determining the mode of EZH2 
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1.1 Breast Cancer 
 
Breast cancer is the most common cancer in women and it is the second leading cause 
of cancer death in women after lung cancer. Breast is constituted of ducts, lobules, adipose, 
connective and lymphatic tissues. Breast cancer is normally arised from ductal or lobular 
tissues (Figure 1.1A). At the initial stage of tumor development, the tumor mass is confined in 
the ductal or lobular structure, it is termed in situ carcinoma. In situ carcinoma usually would 
result in a good clinical outcome as long as it is surgically removed. On the other hand, when 
the cells become invasive and infiltrate to the adjacent tissue, there would be a high 
possibility that it will metastasize to other organs and often results in poor prognosis 
(AmericanCancerSociety, 2011). 
Breast cancer could also be classified into basal-like and luminal subtypes based on 
molecular expression profiling (Perou et al., 2000). These two subtypes are generally viewed 
as different disease entities and have very different intrinsic gene expression patterns. Mainly, 
there are two cell types that exist in the ductal and lobular tissues, namely luminal and 
myoepithelial (Figure 1.1B). Both basal and luminal breast cancer cells are proposed to be 
originated from the luminal lineages but arised at different stages of development. Basal-like 
breast cancer was believed to develop from the luminal progenitor cells that are more 
pluripotent and mesenchymal as compared to the luminal breast cancer that was proposed to 
develop from more differentiated luminal stage (Prat and Perou, 2009). Thus, basal-like breast 
cancer retains the expression of genes that are present in the myoepithelial lineage that was 
branched right before or at the stage of luminal progenitor. On the other hand, luminal breast 
cancer which develops later has lost the traits of myoepithelial cells and instead gained the 

















The heterogeneity of breast cancer was intensively being studied by the advancement 
of gene expression profiling using high throughput technologies. Basal-like and luminal 
breast cancer are now further subcategorized into several subgroups based on the expression 
of specific genes (Lehmann et al., 2011). In addition, more breast cancer subtypes that are not 
categorized to luminal and basal-like also emerged, for instance claudin-low breast cancer 
(Table 1.1 and Table 1.2) (Peddi et al., 2012). In this thesis, my focus will be on the basal-like 
and luminal breast cancer in general. 
  
Figure 1.1 Structure of breast and subtype classification  
A. Anatomy structure of breast organ. (Adapted from: http://www.surgical-
blog.com/breast-cancer-about-breast-cancer-breast-cancer-risk-and-
symptoms/) 
B. Luminal and basal-like breast cancer classification was defined by the 













High level expression of ER and ER-associated genes, 
associated with a favorable clinical outcome. 
Luminal B 
 
Low level expression of ER and ER-associated genes, 
associated with a higher tumor cell proliferation rate and a 




High level expression of HER2 and GRB7, associated with 
a poor outcome before the era of HER2-targeted agents. 
Basal-like 
 
Positive for the expression of basal cytokeratin but 
negative for the expression of luminal- and HER2-related 
genes, associated with a high tumor cell proliferation rate 
and a poor clinical outcome.  
Normal-like 
 
Similar expression compared to normal breast, suspicious 
for normal cell contamination. 
Claudin-low 
 
Lack the expression of claudin proteins that are implicated 
in cell-cell adhesion, but high expression of EMT and 
putative stem cell markers, associated with ER and HER2 
negativity but low in basal cytokeratin expression. 
Table 1.1: Intrinsic subtypes of breast cancer(Peddi et al., 2012) 
Subtype 
Gene expression profile 
Basal-like 1 (BL-1) 
 
High in the expression of genes involved in cell cycle 
progression, cell division, and DNA damage response 
pathways. 
Basal-like 2 (BL-2) 
 
High in the expression of genes involved in cell cycle 
progression, cell division, and growth factor signaling. 
Immunomodulatory (IM) 
 
High in the expression of genes involved in immune 
processes and cell signaling. 
Mesenchymal (M) 
 
High in the expression of genes involved in motility and 
extracellularmatrix. 
Mesenchymal stem-like (MSL) 
 
High in the expression of genes involved in motility, 
extracellular matrix, and growth factor signaling; 
consistent with claudin-low Intrinsic subtype. 
Luminal androgen receptor 
(LAR) 
 
High in the expression of genes involved in hormonally 
regulated pathways. 
Table 1.2: Six subtypes of triple negative breast cancer based on gene expression 






1.1.1 Basal-like breast cancer (BLBC) 
  
About 15% of breast cancer is categorized as basal-like breast cancer (BLBC) (Rakha 
et al., 2008). BLBC could be distinguished from luminal breast cancer by 
immunohistochemistry staining of the markers that are expressed specifically in basal-like 
cells, for instance keratin 5, keratin 6, and keratin 17. Another common characteristic of 
basal-like breast cancer cells is the lack of expression of several surface receptors like 
estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and in most of the 
cases progesterone receptor (PR). Due to the negativity of the expression of these receptors, 
this subtype of breast cancer is also known as triple-negative breast cancer (TNBC) (Foulkes 
et al., 2010). About 70-80% of BLBC cells are TNBC and more than 80% of TNBC belongs 
to BLBC. Furthermore, there are great similarities shared between TNBC and BLBC in terms 
of clinical prognosis and therapeutic responses (Badve et al., 2011). In fact, many clinical 
trials that were supposedly performed in BLBC were carried out in patients stratified by 
triple-negativity status due to convenient and pragmatic purposes (Rakha et al., 2008; 
Santana-Davila and Perez, 2010). Therefore, although it was reported that the overlap 
between these two breast cancer types is not complete, many papers still used BLBC and 
TNBC interchangeably. Concordantly, in the introduction, I will summarize the findings in 
BLBC and TNBC in a collective manner. 
 
1.1.1.1 Aggressive phenotypes of BLBC 
 
BLBC frequently occurs in young women especially from black and Hispanic races 
compared to other ethnic groups (AmericanCancerSociety, 2011). Patients with BLBC tend to 
have adverse prognosis and early relapse within five years after treatment (Fig 1.2) (Rakha et 
al., 2008). The recurrent tumors are always found to be at the distal organs from breast, 





disseminate from its primary niche to other sites of the body to form secondary tumors 
(Nguyen et al., 2009). It happens when tumor progresses to higher grade and attain invasive 
and aggressive properties. Metastasis is the main cause that renders this disease to be 
incurable. 
Clinical observation has revealed that different types of cancer could have preference 
towards the sites where they metastasize to, this phenomenon termed “organ tropisms” (Chu 
and Allan, 2012; Nguyen et al., 2009). For instance, breast cancer preferentially metastasizes 
to lymph nodes, lungs, brain, liver, and bone; whereas prostate and colorectal cancers tend to 
spread to bone and liver, respectively. Interestingly, it was reported that different subtypes of 
breast cancer could too have different preference towards sites of metastasis: BLBC has 
higher propensity to spread to brain, lung, and liver whereas luminal breast cancer has higher 




Two factors were proposed to influence the aggressiveness of BLBC, the 
mesenchymal phenotype and the enriched population of cancer stem cells. Under normal 
circumstances, epithelial cells are well-organized and reside within the basement membrane 
Figure 1.2 Hazard rates for distant recurrence of TNBC and non-TNBC breast 






with regular apical basolateral polarity. During cancer progression, the cancer cells would 
undergo a process called epithelial-mesenchymal transition (EMT) (Kang and Massague, 
2004; Thiery, 2002), in which the cells would gradually lose the expression of cell-cell 
junction molecules (e.g., E-Cadherin) , which results in the disorganization of the cell polarity 
and the gain of cell motility (Figure 1.3). The cells would then invade out from the primary 
tumor site, migrate and colonize distal organs to form secondary metastases. It was 
discovered that EMT features happen more frequently in BLBC (Sarrio et al., 2008) Many of 
the BLBC cell lines are locked in mesenchymal state with characteristics which are highly 
motile, invasive, lack of cell-cell adhesion junction and often appear to have spindle-shaped 
morphology.   
 
 
Another factor that contributes to the aggressiveness of BLBC is the high proportion 
of cancer stem cells (CSC) in BLBC (Honeth et al., 2008). CSC represents a population of 
cells that is able to initiate tumor formation and subsequent tumor maintenance in vivo. As 
CSC is found to be resistant to chemotherapy, it has been regarded to be the main culprit of 






tumor relapse. The first isolation of CSC in breast tumors was achieved by Al-Hajj et al. via 
fluorescence-activated cell sorting based on the expression of the surface markers 
CD44+/CD24-/low.(Al-Hajj et al., 2003) The isolated cells were demonstrated to be able to 
generate tumor in vivo with as few as 100 cells injected. Strikingly, BLBC has been reported 
to be enriched in CD44+/CD24-/low cell population (Honeth et al., 2008; Park et al., 2010). 
This could serve as the cause of clinical observation that BLBC tends to have early relapse 
after chemotherapy due to the presence of high fraction of CSC.  
CSC was shown to have increased metastatic propensity in vitro and in vivo, albeit 
mechanism remains unclear (Chu and Allan, 2012). Intriguingly, it was suggested that EMT 
could accelerate the formation of CSC (Floor et al., 2011; Morel et al., 2008). A recent paper 
even proposed that EMT cells and CSC are overlapped and among the EMT cells 
disseminated from the tumor only the most competent CSC will eventually succeed to 
metastasize (Floor et al., 2011). Although the relationship between EMT and CSC is complex 
and perplexing, their association with cancer metastasis is evident. As BLBC is enriched in 
both CSC and EMT phenotypes, propensity to metastasize is also unquestionable. 
 
1.1.1.2 Pathways driving BLBC oncogenicity 
 
Cancer development and progression often involves the activation of oncogenic 
pathways and inactivation of tumor suppression pathways by genetic or epigenetic changes. 
Different cancer types may have dependency on the dysregulation of different signaling 
pathways. In BLBC, several pathways are known to be dysregulated and contributed to its 
progression, for instance silencing of ER and BRCA1, overexpression or activation of EGFR, 
VEGFR, SRC, PI3K, and NF-κB pathways.  
As mentioned earlier, more than 80% of BLBC is TNBC, lacking the expression of 
ER, PR and HER2. In fact, many studies have demonstrated that the absence of ER is one 
major factor of the aggressiveness of BLBC (Fearon, 2003; Rochefort et al., 1998). 





aggressiveness of the cells . The mechanism behind ER-mediated suppression of cancer 
invasiveness is not largely understood, although several findings have demonstrated that ER 
negatively regulates the expression of the components in NF-κB pathways, including RelB, 
IL6, and IL8 (Freund et al., 2003; Freund et al., 2004; Stein and Yang, 1995; Wang et al., 
2007). NF-κB pathway was long known to be constitutively activated in BLBC, and it is 
shown to be associated with the aggressiveness of this subtype of breast cancer (Gionet et al., 
2009; Huber et al., 2004; Karin and Greten, 2005). However, the mechanism underlying the 
constitutive activation of NF-κB pathway is not well understood.  
EGFR is frequently overexpressed in BLBC (Dent et al., 2007). In some studies, 
EGFR is even proposed to be one of the molecular markers of BLBC apart from the 
negativity of ER, PR, HER2 and the expression of basal keratins (Shao et al., 2011; 
Siziopikou and Cobleigh, 2007). Recent reports indicated that the overexpression EGFR 
protein level is largely due to gene amplification in BLBC (Gumuskaya et al., 2010; Shao et 
al., 2011). As a consequence of EGFR overexpression, EGFR signaling was found to be 
overactivated in BLBC. Besides promoting the survivability of cancer cells, the activation of 
EGFR pathway in BLBC was shown to enhance the mesenchymal phenotypes of this cancer 
subtype (Ueno and Zhang, 2011). 
Tumor cells are fast growing cells but the growth of tumor mass is restricted by the 
availability of nutrients and oxygen. Thus, when the tumor mass grows to a certain size, 
typically 1-2mm (McDougall et al., 2002), tumor cells would secrete growth factors like 
fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) that will 
induce a process called angiogenesis. Angiogenesis is one crucial process during tumor 
progression, involving the development of blood vessels at the site where tumor mass grows. 
The blood capillaries that grow into the tumor mass would nourish the tumor cells to support 
further tumor growth. Besides nutrients and oxygen supply, angiogenesis was indicated to 
promote metastasis. Cancer cells that gain metastatic potential could invade into the blood 





was demonstrated to correlate with the development of secondary metastatic tumors 
(Cristofanilli et al., 2004).  
SRC is a non-receptor tyrosine kinase, which would relay phosphorylation signaling 
upon activation by growth factor receptor. As consequences of dysregulated SRC activation, 
the cells would gain oncogenic responses such as increase in cell proliferation, survivability, 
angiogenicity, and motility (Gelman, 2011; Wheeler et al., 2009). It was reported that SRC is 
overactivated in BLBC, and BLBC cells were found to be more susceptible for SRC 
inhibitors (Finn et al., 2011; Tryfonopoulos et al., 2011), implicating the dependency of 
BLBC on the dysregulated SRC activity. 
Besides the abovementioned factors/pathways that contribute to the aggressiveness of 
BLBC, there are also pathways that are known to be governing the survivability or 
proliferation specifically in BLBC subtype. BRCA1 is a tumor suppressor, which functions to 
repair double-stranded breaks in DNA for instance during the events of homologous 
recombination. BRCA1 expression could be silenced by genetic (inactivating mutation) or 
epigenetic (promoter hypermethylation and microRNA regulation) mechanisms (Rakha et al., 
2008; Rice et al., 1998; Shen et al., 2009; Shen et al., 2010). Loss of the expression of 
BRCA1 leads to error-prone DNA repair, thereby increasing the risk of genetic mutations and 
hence predisposed to cancer development. It was discovered that breast cancer that arises 
from BRCA1-deficient cells shares great similarity to BLBC in terms of clinical 
characteristics and intrinsic gene expression (Santana-Davila and Perez, 2010). Although it is 
unclear of the cause and effect relationship between BRCA1-associated breast cancer and 
BLBC, some reports have suggested that BLBC is more tolerable to the deficiency of BRCA1 
(Bryan et al., 2006; Dabbs et al., 2006) while some other reports have suggested that loss of 
BRCA1 leads to the development of cancer with more stem-cell like properties (Foulkes, 





When BLBC cells were defined based on the triple-negativity status, researchers 
discovered that there is a subgroup of BLBC segregated with luminal breast cancer based on 
expression profiling despite of the absence of ER, PR, and HER2 (Doane et al., 2006). 
Subsequently, it was demonstrated that the expression of androgen receptor (AR) causes the 
similarity of this BLBC subgroup with luminal breast cancer, therefore this subtype of breast 
cancer is named as luminal androgen receptor (LAR). Investigators reported that the 
expression of AR in LAR renders the proliferative advantage of this cancer subtype. 
In addition to the aforementioned pathways that are more specifically being 
activated/inactivated in BLBC/TNBC compared to other cancer subtypes, many other 
oncogenic pathways are also revealed to play essential roles in promoting breast cancer in 
general, including both BLBC and luminal breast cancer (Cleator et al., 2007; Santana-Davila 
and Perez, 2010). For example, PI3K/AKT/mTOR and Ras/MEK/MAPK pathways were 
known to promote survivability and proliferation in breast cancer. Ordinarily, the pathways 
that are dysregulated are not mutually exclusive, multiple oncogenic pathways could be 
turned on and multiple tumor suppressor pathways could be turned off simultaneously and 
contributed to oncogenesis. 
 
1.1.1.3 Current therapy of BLBC 
 
Most BLBC lacks the expression of ER, PR, and HER2, rendering this cancer 
subtype irresponsive to receptor targeted therapy.  Hence, chemotherapy is the mainstay 
therapeutic option for the treatment of this subtype of breast cancer (Berrada et al., 2010). 
Chemotherapeutic drugs are also known to be cytotoxic drugs that attempt to kill fast growing 
cells. In the case of neoplasia, chemodrugs are effective in the treatment by exploiting the fact 
that the tumor cells proliferates much faster than normal cells. There are several types of 
chemotherapeutic agents which are frequently used in neoadjuvant or adjuvant therapy of 





compounds extracted from Streptomyces bacteria, normally act by intercalating DNA/RNA 
and interfere with cell replication (e.g., doxorubicin); (ii) taxanes – compounds produced by 
plants of the genus Taxus, act by disrupting microtubule function (e.g., paclitaxel); (iii) 
platinum agents – DNA damaging agents, act by inducing DNA repair mechanisms and in 
turn inducing apoptosis when repair is impossible (e.g., cisplatin). 
Among different subtypes of breast cancer, BLBC patients were revealed to benefit 
most from chemotherapy with higher pathological complete response (pCR), an indication of 
the complete recession of detectable tumor mass (Foulkes et al., 2010). However, the overall 
survival rate of BLBC patients does not appear to be favorable due to early tumor relapse 
(Dent et al., 2007). The recurrent BLBC tumors are usually metastatic and appear more 
aggressive. As a result, less than 30% of the women with BLBC are able to survive five years. 
Therefore, intensive research efforts are focused on the identification of druggable targets in 
TNBC and develop better pharmaceutical strategies in BLBC treatment.   
Thus far, molecular targeted therapy has limited success in the treatment of BLBC. 
One example is poly-(ADP ribose) polymerase (PARP) inhibitor which was once believed to 
be a promising targeted drug in treating BLBC. About 20% of BLBC was reported to have 
BRCA1-deficiency, either via gene mutation or gene underexpression. As mentioned earlier, 
BRCA1 is responsible for homologous DNA repair. Studies have reported that tumors with 
BRCA1 deficiency showed synthetic lethality with PARP inactivation, which would 
otherwise function to repair DNA through base-excision (Glendenning and Tutt, 2011). 
However, during phase III clinical trial of Iniparib (PARP inhibitor), no favorable outcome 
was observed in BLBC treatment albeit the mechanism of resistance is still unknown (Fojo et 
al., 2011; Guha, 2011).  
Another example of targeted therapy is EGFR inhibitors (Harari, 2004), which 
encompass EGFR-specific antibodies (eg. Cetuximab) and small molecule inhibitors (eg. 





that more than 50% of TNBC harbors EGFR overexpression and hyperactivation. EGFR is a 
receptor tyrosine kinase (RTK) that is responsible for the activation of multiple downstream 
oncogenic kinase signalings such as AKT and ERK upon activation by cytokines like EGF 
(Foley et al., 2010). These signalings lead to cancer progression for instance increase in cell 
proliferation, invasiveness, and survivability. Nevertheless, similar to the case of PARP 
inhibitor, EGFR inhibitors showed limited favorable response during clinical trials (Hudis and 
Gianni, 2011). Many possible mechanisms was reported including mutation of EGFR that 
affects the binding of the inhibitors, nuclear localization of EGFR that renders inefficient cell 
surface binding of Cetuximab (Wheeler et al., 2010).  The disappointing clinical outcomes of 
EGFR inhibitors underscore the need of a revised EGFR targeted strategy. 
In addition to these approaches, other oncogenic factors that were known to be 
overactivated in BLBC were also being targeted (Berrada et al., 2010; Peddi et al., 2012). For 
instance, SRC inhibitor (Dasatinib), VEGF inhibitor (Bevacizumab), and AR inhibitor 






1.1.2 Luminal breast cancer 
 
Majority (75%-80%) of breast cancer is characterized as luminal breast cancer. 
Luminal breast cancer cells are normally characterized by the expression of luminal 
cytokeratin for instance CK7, CK8, CK18, and CK19 (Perou et al., 2000). In addition to these 
markers, it is also generally recognized that luminal breast cancer cells express PR, ER and its 
associated cofactors like FoxA1 and GATA3 (Badve and Nakshatri, 2009).  
Clinically, luminal breast cancer is further subcategorized into two groups, namely 
luminal A and luminal B subtypes. These two subtypes could be distinguished by 
proliferative signatures such as CCNB1, MK167 and MYBL2, which expressed higher in 
luminal B subtype (Cheang et al., 2009). It was also suggested that high expression of HER2 
and Ki67 (another proliferative marker with immunohistochemistry antibody available), also 




Most of the luminal breast cancer cells appear epithelial with high expression of cell 
adhesion molecules like E-cadherin (Fearon, 2003). As a result, luminal cells are generally 
less invasive than BLBC. Similarly, by clinically comparing luminal breast cancer to BLBC, 
the former is less aggressive with lower frequency of tumor recurrence in five years after 
surgery (Andre and Pusztai, 2006). Furthermore, luminal breast cancer patients would 
normally experience local tumor recurrence before distant recurrence. Hence, local recurrence 
in luminal breast cancer could serves as an observation predictive of distal metastasis. When 
comparison is made between the two luminal subtypes, it was observed that luminal B is 





Interestingly, it was discovered that there are discordance of ER, PR, and HER2 
status between the primary and recurred metastatic breast cancer (Arslan et al., 2011). Most 
of the time, these receptors are lost in relapsed metastatic tumors, particularly for the case of 
PR (Broom et al., 2009). It was suggested that most tumors represent a heterogeneous cell 
population. Although luminal breast cancer cells harbor the expression of ER, PR, and HER2, 
it was reported that more than 50% of luminal breast cancer consists of about 1% of ER-, PR- 
negative, and CK5-positive cells that resemble BLBC (Haughian et al., 2012). This 
subpopulation of cells is known as luminobasal cells. Thus, it was speculated that this 
luminobasal minor population is the culprit accountable for the resistance of receptor-targeted 
therapy (Kabos et al., 2011), which survives and relapses after such therapy.  
 
1.1.2.2 Pathways driving luminal breast cancer oncogenicity 
 
In past decades, research efforts in luminal breast cancer were focused on ER, PR, 
and HER2. Researchers found that ER positively regulates several aspects of luminal breast 
cancer especially cell survivability and proliferation (Ali and Coombes, 2000; Sommer and 
Fuqua, 2001). ER is a family of nuclear hormone receptor, which would translocate into the 
nucleus to regulate gene transcription upon activation of its ligands for instance, estrogen. It 
could either activate or suppress the expression of its target genes by binding to its co-
activators or co-repressors.  GATA3 and FoxA1 are two essential collaborators of ER (Badve 
and Nakshatri, 2009). Investigators reported that GATA3 and FoxA1 often serve as 
pioneering factors to aid ER loading to the DNA binding sites of its target genes. Loss of 
either GATA3 or FoxA1 was demonstrated to disrupt ER target gene regulation. Cyclin D1 
and c-myc (Wang et al., 2011) are two well known examples of ER that promote cell 
proliferation and survival, respectively. Similar to ER, PR is also known to promote 
proliferation in breast cancer (Obr and Edwards, 2012), although the exact mechanism of how 





Perplexingly, ER and PR were shown to suppress luminal breast cancer progression 
to the advanced metastatic stage. One proposed mechanism is through ER suppression of 
Snail expression (Fearon, 2003), an EMT driver, which otherwise would repress E-cadherin 
expression. As a result, ER-positive breast cancer cells are usually associated with high 
expression of E-cadherin and adopt epithelial and non-invasive phenotypes. In addition, ER 
was also reported to repress RelB (Wang et al., 2007), a member of NF-κB that was proposed 
to function as a metastatic driver. On the other hand, how PR represses EMT was not well 
understood.  
HER2 is implicated in luminal B subtype of breast cancer. HER2 was revealed to 
regulate a wide array of downstream signaling pathways including MAPK, PI3K, and STAT 
(Ross and Fletcher, 1998; Ross et al., 2003), that are known to promote proliferation, survival, 
and invasion during oncogenesis. Indeed, HER2 expression in luminal B breast cancer was 
suggested to be one of the factors causing luminal B to be more aggressive than luminal A 
breast cancer (Cheang et al., 2009). 
1.1.2.3 Current therapy 
 
As luminal breast cancer is largely dependent on ER for survival and proliferation, it 
is not inconceivable that the main approach of luminal breast cancer therapy is endocrine 
therapy targeting ER. There are two types of endocrine therapy targeting ER (Shao and 
Brown, 2004), (i) selective estrogen receptor modulators (SERM), act as ER antagonists (e.g., 
tamoxifen and raloxifene); (ii) aromatase inhibitors, act by inhibiting estrogen synthesis from 
androgen (e.g., anastrozole). In fact, the more commonly adopted therapy using tamoxifen has 
produced much efficacy in treating luminal breast cancer. Based on breast cancer statistics in 
USA, the breast cancer death rate in white American diverged significantly from African 
American starting from 1990s (Fig 1.4.). Two reasons were proposed to explain for this 
difference (Jatoi et al., 2003; Menashe et al., 2009): (i) greater usage of mammography by 





which could benefit white American more as these patients tend to have luminal breast cancer 
(ER-positive) compared to black American whom often suffer from BLBC (ER-negative). 
  
 
Nevertheless, in 2000s, a subset of patients was discovered to develop resistance 
towards tamoxifen. Soon after, it was revealed that the elevation of HER2 level in the treated 
luminal breast cancer could be accountable for the resistance (Shou et al., 2004). Therefore, 
investigators attempted to combine treatment of tamoxifen with trastuzumab (Romond et al., 
2005), a HER2 inhibitor, and the effectiveness of this strategy was evident in the clinical 
outcomes.  
Although HER2 expression is elevated in luminal B breast cancer, trastuzumab did 
not yield a satisfactory outcome clinically (Nguyen et al., 2008). A possible reason is that 
HER2 is only an auxiliary pathway driving the oncogenicity of this subtype of breast cancer. 
Many other oncogenic pathways activated in this cancer subtype appear to be resulted from 
the activation of various growth factor receptors. Hence, it was suggested that other kinases 
inhibitors for instance PI3K inhibitor could be a better candidate for the treatment (Loi, 2008) 
as these kinases lie at the convergent point downstream of the different growth factor 
receptors in the signaling pathways. 
  
Figure 1.4 Trends of death rates in female breast cancer patients in United 








In 1980s, enhancer of zeste (E(Z)) was first found to play a role in suppressing the 
differentiation of cells into specific tissues, thereby affecting the development of Drosophila 
melanogaster (Jones and Gelbart, 1990). In 1990s, researchers discovered that the human 
homolog of E(Z), named Enhancer of Zeste Homolog 2 (EZH2) is involved in the 
transcriptional repression of homeobox gene expression (Hobert et al., 1996), to maintain 
stemness and inhibit differentiation of the cells. It was found that EZH2 deficient mice are 
embryonic lethal, indicating its importance in early development. In adults, EZH2 remains 
essential as it was reported to be involved in the self-renewal of hematopoietic stem cells that 
would populate blood cells from myeloid and lymphoid lineages. 
 In addition, EZH2 was also shown to participate in X-chromosome inactivation. In 
female mammals (Plath et al., 2003), X-chromosome inactivation is a crucial event during 
development to achieve dosage compensation by inactivating one of the two copies of X-
chromosomes. During the inactivation process, a non-coding RNA called X inactivation 
specific transcript (Xist) would be transcribed and bound to the inactivating X-chromosome. 
This facilitates the recruitment of PRC2 and subsequent H3K27 trimethylation, which would 






1.2.1 EZH2 and PRC2 complex 
 
EZH2 is the catalytic component of polycomb repression complex 2 (PRC2) (Simon 
and Lange, 2008). The protein structure of EZH2 is illustrated in Fig 1.5. At the N-terminal of 
the protein, there are two domains, which are reported to be responsible for the interaction 
with two other components of PRC2: (i) DomainI interacts with embryonic ectoderm 
development (EED) and (ii) DomainII interacts with Suppressor of Zeste 12 (SuZ12). EZH2 
protein also consists of a nuclear localization signal (NLS) that allows it to transport into the 
nucleus. At the C-terminal, there are highly conserved cysteine-rich and SET domains, which 
were demonstrated to have methyltransferase activity (Cao and Zhang, 2004a). However, it 
was indicated that EZH2 has no enzymatic activity on its own (Cao and Zhang, 2004b; Muller 
et al., 2002). Only by forming a complex with EED and SuZ12, EZH2 could exhibit its 
methyltransferase activity. In fact, in the absence of EED or SuZ12, EZH2 protein stability 
was demonstrated to be disrupted. EZH1, a close relative of EZH2, was also being discovered 
in 1990s (Abel et al., 1996; Laible et al., 1997). However, only recently it was reported that 
EZH1 could also form PRC2 complex with EED and SuZ12 and exert methyltransferase 





EED contains WD40 repeat domain that was shown to have affinity binding to 
methylated histone 3 lysine 27 (H3K27), thereby aiding in the propagation of H3K27 
trimethylation (H3K27me3) by PRC2 complex (Margueron et al., 2009). On the other hand, 
although SuZ12 was demonstrated to be essential for PRC2-mediated H3K27 trimethylation 
(Cao and Zhang, 2004b), the exact function of SuZ12 in the complex is unclear. Besides 






EZH2, EED, and SuZ12 being the core complex of PRC2, several research groups had 
revealed additional subunits in PRC2, such as RBBP4/7, Jarid, and PCL, which help to 








Figure 1.6 PRC2 complex formed by polycomb protein components. Modified 






1.2.2 Modes of transcriptional repression 
 
PRC2-catalyzed H3K27me3 near the promoter of its target genes is associated with 
transcriptional repression of these genes (Cao et al., 2002). There are several mechanisms 
proposed to be downstream of this histone methylation mark, which facilitate the silencing of 
the target gene expression. These include histone ubiquitination, DNA methylation, histone 
deacetylation, and chromosome remodeling. 
1.2.2.1 Histone ubiquitination 
 
As a consequence of trimethylation of H3K27 by PRC2 complex, another family of 
polycomb group (PcG) chromatin modifying complex, PRC1, would be recruited by the 
histone mark to catalyze monoubiquitination of histone H2A at lysine 119 (H2AK119Ub1) 
(Wang et al., 2004). Two RING-finger domain-containing proteins, RING1A and RING1B 
are the catalytic subunits of PRC1, in which the latter being the more predominant and 
efficient E3 ubiquitin ligase (Buchwald et al., 2006). B lymphoma Mo-MLV insertion region 
1 (BMI1) is another core component of PRC1 complex that was reported to be essential for 
RING1B ubiquitin ligase activity (Cao et al., 2005). Importantly, PRC1 also contains 
chromobox homologues (CBX) proteins, which are crucial in binding to H3K27me3 mark. 
Studies have revealed that PRC1 mediated ubiquitination could lead to chromatin compaction 
(Francis et al., 2004) and impede transcriptional elongation (Stock et al., 2007), thereby 
leading to the repression of target gene expression. 
1.2.2.2 DNA methylation 
 
It was revealed that PRC2 complex could interact and thus recruit DNA methyl-
transferases (DNMTs) to the target genes (Vire et al., 2006). DNMTs represent a family of 
proteins that catalyzes methylation on cytosine residues in the CpG islands (Robert et al., 





reading frames. Upon methylation at CpG islands, the associated genes would be silenced by 
impeding direct binding or transcription factors to the promoter. 
1.2.2.3 Histone deacetylation 
 
In addition, PRC2 was also found to have direct physical interaction with HDACs 
and thus able to recruit HDACs to the target genes (Simon and Lange, 2008). Histone tails are 
positively charged due to high composition of Arginines and Lysines. On the other hand, 
DNA is highly negatively charged due to the presence of the phospho groups from phospho-
diester backbone. As a consequence, when negatively charged DNA is wound around 
positively charged histones, the ionic bonding allows strong binding and causes the 
compaction of the chromatin, leading to higher level of the chromatin compaction and 
silencing of the genes. 
1.2.2.4 Chromosome remodeling 
 
Chromatin remodeler is a class of proteins that regulate nucleosome positioning and 
the subsequent transcriptional event. In cancers, SWI/SNF, a family of chromatin remodeling 
complexes, was frequently mutated or inactivated. This was found to be correlated with the 
suppressed expression of tumor suppressor genes like INK4A (Kia et al., 2008). It was found 
that the occupancy of PcG proteins could block the recruitment of SWI/SNF (Wilson and 
Roberts, 2011). The antagonism between SWI/SNF and EZH2 was further evidenced by 
another study demonstrating that the loss of SNF5 could lead to elevated expression of EZH2 
and the in vivo tumorigenicity induced by SNF5 knockout could be rescued by EZH2 






1.2.3 EZH2 and cancers 
 
The oncogenic roles of EZH2 were first demonstrated in prostate cancer by a research 
group lead by Chinnaiyan in 2002 (Varambally et al., 2002). They found that EZH2 is 
overexpressed in prostate cancer and the overexpression is positively correlated with tumor 
stages. Higher expression of EZH2 in patient tumors confers worse prognosis. In the 
subsequent years, research on EZH2 intensified and EZH2 is now found to be overexpressed 
in multiple types of cancers including colon, bladder, lung, breast and prostate cancers 
(Figure 1.7).  
In addition, ectopic overexpression of EZH2 in immortalized cell lines was 
demonstrated to be sufficient to promote neoplastic transformation (Kleer et al., 2003), 
indicating its role in early tumorigenic event. Further ectopic overexpression of EZH2 in 
weakly metastatic cancer cell lines was shown to enhance the motility and invasiveness of 
cancer cells (Collett et al., 2006; Varambally et al., 2002), implying that EZH2 also plays an 










Figure 1.7 Overexpression of EZH2 in multiple cancer types. Blue bars, Normal 






1.2.3.1 Transcriptional repression of tumor suppressor genes 
 
The most well known mechanism behind EZH2-driven oncogenesis is via the 
repression of tumor suppressor gene expression by PRC2-dependent H3K27 trimethylation. 
The first evidence was reported in prostate cancer in which EZH2 was demonstrated to 
repress the expression of E-cadherin (Cao et al., 2008). EZH2-mediated silencing of E-
cadherin causes EMT transition, thereby inducing cancer cell invasiveness. To date, EZH2 
has been shown to repress multiple tumor suppressors that regulate different pathways in 
cancers (Fig 1.8). These target genes include BIM and FBXO32 that antagonize cell survival 
(Wu et al., 2011; Wu et al., 2010); DACT3 and DKK that suppress cell proliferation through 
modulating Wnt pathway (Hussain et al., 2009; Jiang et al., 2008); INK4A that induces 
senescence (Agherbi et al., 2009; Bracken et al., 2007); DAB2IP that inhibits invasion by 
repressing NF-κB and Ras pathways (Min et al., 2010); and VASH1 that suppresses 









Figure 1.8 EZH2 mediates silencing of multiple genes involved in various 






1.2.3.2 Histone methylation-independent functions 
 
Besides transcriptional repression of tumor suppressors through H3K27me3, EZH2 
was reported to have histone methylation independent functions which could lead to 
tumorigenesis. I-hsin Su et al. reported a cytosolic role of EZH2 complex, which involves the 
regulation of growth factor receptor-induced actin polymerization (Su et al., 2005). Such 
regulation requires the interaction between VAV1, a GTP/GDP exchange factor and 
EZH2/EED/SuZ12 complex in the cytoplasm. However, the function of EZH2 is still 
dependent on the methyltransferase activity of EZH2. As EZH2 could regulate actin 
polymerization, the authors implied that cancer cells in which EZH2 is overexpressed could 
have enhanced invasiveness arising from this regulation. 
Another histone methylation independent function was reported by Shi Bin et al. 
They demonstrated that EZH2 has transactivating function in the nucleus by bridging the 
interaction between estrogen receptor and β-catenin (Shi et al., 2007). As the outcome, the 
transcriptional activity of these two transcription factors could be promoted, thereby 
enhancing the expression of the target genes like c-myc and cyclin D1, which would in turn 
enhance cancer cell proliferation. Interestingly, it was found that this function of EZH2 is 
independent of the methyltransferase function and does not require the engagement of other 






1.2.4 Regulation of EZH2 in cancers 
 
Currently, EZH2 is well-recognized as an oncogene in human cancers. Many papers 
have focused on how EZH2 is overexpressed, how its methyltransferase activity is regulated, 
and how EZH2 is directed to its targets in cancer cells.  
1.2.4.1 Regulation of EZH2 expression 
 
The mechanisms behind the overexpression of EZH2 in cancers could be dissected 
into three hierarchies: (i) transcriptional level; (ii) post-transcriptional mRNA level; and (iii) 
protein level. 
At transcriptional level, EZH2 was found to be regulated by several transcription 
factors that are known to be overexpressed or overactivated in cancers. E2F1 is a very well-
characterized transcription factor that exhibit dual roles in regulating cell survivability. It was 
revealed that E2F1 promote the transcriptional expression of EZH2 (Wu et al., 2010), which 
will inhibit E2F1-induced cell death by repressing Bim expression. Another group discovered 
that EZH2 is a direct transcriptional target of Elk1 under the regulation of Ras/MAPK/ERK 
pathway (Fujii et al., 2011). Besides, EZH2 expression level was revealed to be negatively 
regulated by p53 (Tang et al., 2004). More than 50% of human cancers harbor 
underexpression or mutation of p53, which in turn results in the release of transcriptional 
repression and subsequent elevation of EZH2 expression in these cancers.  
The mRNA level of EZH2 could be further regulated by microRNAs (miRNAs), a 
subcategory of non-coding RNA that binds to 3’-untranslated region of mRNA to promote 
mRNA degradation by Dicer-associated machineries. MiR-101, a miRNA whose expression 
is lost during prostate cancer progression, was demonstrated to target EZH2 mRNA for 





by miR26a, which the latter is suppressed by c-myc that is frequently overexpressed in 
cancers (Sander et al., 2008).  
More recently, Zoabi et al. discovered that EZH2 and other components of PRC2 
complex could be induced for protein degradation by a ubiquitin ligase, PRAJA1 (Zoabi et al., 
2011). Interestingly, PRAJA1 itself is repressed by PRC2 complex and could be induced in 
cancer cells upon the treatment of EZH2 inhibitor, 3-Deazaneplanocin A (DZNep). 
1.2.4.2 Regulation of EZH2 activity 
 
The regulation of EZH2 methylation activity was mentioned in several studies. A 
research group lead by Mien-Chie Hung first discovered that EZH2 could be modified post-
translationally by AKT through serine phosphorylation (Cha et al., 2005). In that study, the 
researchers noticed that the activated AKT could phosphorylate EZH2 at Serine 21, which 
would lead to the reduction of EZH2 binding to histone H3 and the subsequent H3K27 
trimethylation. It was suggested that the released pool of EZH2 complexes would then be able 
to methylate other non-histone substrate that could drive tumor progression.  
A few years later, the same group reported another phosphorylation site of EZH2 at 
Threonine 487 by cyclin-dependent kinase 1 (CDK1) (Wei et al., 2011). This phosphorylation 
causes the dissociation of EZH2 from PRC2 complex and thereby reducing H3K27me3 and 
the repression of the target genes. This regulation was shown to have negative effects on 
cancer cell migration and osteogenic differentiation of mesenchymal stem cells. On the 
contrary, almost at the same time, another group lead by Haojie Huang discovered that CDK1 
and CDK2 could phosphorylate EZH2 at Threonine 350 (Chen et al., 2010). In contrast to 
phosphorylation at Threonine 487, the phosphorylation at Threonine 350 leads to increase 
DNA binding of EZH2 and the associated H3K27me3 mark and as a result, the invasive 





In addition to phosphorylation, EZH2 was found to be sumoylated at multiple sites in 
vitro (Riising et al., 2008). However, the identity of the E3 ligase that is responsible for the 
sumoylation of EZH2 is still not known. Moreover, the occurrence and function of such 
modification in in vivo is still unclear. Further investigations need to be done to clarify these 
questions. 
Besides post-translational modifications, it was discovered that mutations of EZH2 in 
cancer cells could impact its methylation activity. In B-cell lymphoma, EZH2 has a recurrent 
mutated site at Tyrosine 641 (Y641) that reside in the catalytic SET domain (Morin et al., 
2010). This point mutation is found to be cancer-specific as it is only present in tumor DNA 
but not the normal counterpart. When Y641 is mutated, the methylation activity of EZH2 
reduces drastically. Very often, B-cell lymphoma cells that harbor this mutation are normally 
heterozygous, in other words, only one out of the two homologous chromosomes harbors this 
mutation, while the other copy of EZH2 remains unmutated. It was later discovered that while 
wild type EZH2 exerts higher methylation activity on unmethylated H3K27 compared to 
mono- and di-methylated H3K27, EZH2 Y641 mutant shows higher activity on dimethylated 
H3K27 and almost no activity towards unmethylated or mono-methylated counterparts (Yap 
et al., 2011). Concordantly, when a tumor cell expresses of both wild type and Y641 mutant 
EZH2,   H3K27 trimethylation activity will be enhanced as a result of the cooperation 
between the two variants. Another mutation of EZH2 at A677 was also discovered in 
lymphoma to synergize with Y641 mutant EZH2 in promoting hypermethylation of H3K27 
(McCabe et al., 2012). 
1.2.4.3 Steering of PRC2 binding to targets  
 
Unlike polycomb complexes in Drosophila that have defined DNA binding motif, 
termed polycomb response element (PRE), polycomb complexes in mammals have less 
defined DNA-targeting signals (Cao et al., 2002). Although EED was found to have DNA 





targets remains undetermined and has become a research focus in past decade. Thus far, two 
mechanisms for EZH2 recruitment to the chromatin were proposed: (i) recruitment by 
transcription factors and (ii) redirection by non-coding RNA (ncRNA). 
Most transcription factors have distinct DNA sequences (or motif) that they would 
have exhibit higher affinity towards and preferentially bind. Upon binding to their respective 
DNA motifs, the transcription factors would then recruit transcriptional co-activators or co-
repressors that facilitate the activation or repression of the target gene expression, respectively. 
EZH2-containing PRC2 complex is one such example of transcriptional co-repressor. Clara 
Hwang et al. demonstrated that EZH2 could physically bind to Repressor of Estrogen 
receptor Activity (REA) and suppress ER-mediated transcription (Hwang et al., 2008). 
Another study reported that IFNα-stimulation resulted in the recruitment of STAT2 and EZH2 
complex to the promoter of DNp73, leading to its suppression (Testoni et al., 2011). A more 
recent study also demonstrated that upon activation of Androgen Receptor (AR), EZH2 and 
HDACs could be recruited together with AR co-repressor, ERG, resulting in genome-wide 
repression of AR target genes (Chng et al., 2012).  
In addition to promoter recruitment of EZH2 complex by transcription factors, EZH2 
binding to specific target genes could also directed by non-coding RNA. A long well-known 
example is the X-chromosome inactivation mediated by PRC2 recruitment to Xist, a non-
coding RNA that is transcribed from the X-chromosome in cis (Plath et al., 2003). More 
recently, HOTAIR, a long non-coding RNA that is transcribed from HOXC locus on 
chromosome 12 and tend to bind to HOXD genes on chromosome 2 in trans to mediate 
HOXD gene repression by directly recruiting PRC2 complex (Kaneko et al., 2010; Rinn et al., 






1.2.5 EZH2 and breast cancer 
 
EZH2 is known to be overexpressed in breast cancer and the overexpression level is 
correlated with breast cancer aggressiveness (Collett et al., 2006). Indeed, EZH2 is 
demonstrated to repress multiple tumor suppressor genes in breast cancer cells such as 
CDKN1C and RUNX3 (Fujii et al., 2008; Yang et al., 2009a). These genes are thought to be 
crucial at the early stage of tumorigenesis. In addition, EZH2 also suppresses CDH1 and 
FOXC1 (Cao et al., 2008; Du et al., 2012), two negative regulators of tumor invasion, which 
might be crucial in advance tumor progression. Based on the evidences in clinical samples, 
EZH2 was even proposed to be the prognostic marker of aggressive breast cancer. 
More recently, evidences pointing to EZH2 being responsible for the expansion of 
breast tumor-initiating cells (also known as cancer stem cells) were emerging. It was shown 
that EZH2 represses the expression of RAD51 (Zeidler and Kleer, 2006; Zeidler et al., 2005), 
a protein that helps to repair DNA double-stranded break. With RAD51 suppressed, genomic 
instability ensues, culminating into the amplification of Raf1 locus. This increases the 
expression of Raf1 and leads to hyperactivation of ERK/β-Catenin pathway, which would in 
turn promote cell survival and proliferation of the breast tumor-initiating cells. 
EZH2 overexpression is found to be more associated with ER-negative breast cancer, 
especially TNBC. Conversely, BRCA1 is often mutated and underexpressed in TNBC. Many 
studies have reported potential crosstalk between EZH2 and BRCA1 in TNBC (Gonzalez et 
al., 2011; Gonzalez et al., 2009; Kleer, 2009; Puppe et al., 2009). It was indicated that EZH2 
represses BRCA1 function and the decrease in cell proliferation as a result of EZH2 inhibition 
requires the presence of BRCA1. It was further demonstrated that EZH2 promote nuclear 
export of BRCA1 to facilitate genomic instability. It was also shown that EZH2 inhibition by 
DZNep is more effective in suppressing growth of BRCA1-deficient breast cancer cells, 








1.3.1 NF-κB as a family of transcription factors 
 
Nuclear Factor κB (NF-κB) represents a family of transcription factors that consisting 
of Rel-homology domain, which enables these transcription factors to form dimers and bind 
to DNA for transcription (Gilmore, 2006). There are five family members of NF-κB which 
could be categorized into two types (Figure 1.9): (i) with transactivational activity, includes 
RelA, RelB, and Rel; (ii) without transactivational activity, includes p50 and p52.  These five 
family members could form dimers with different combinations to regulate the expression of 
specific target genes. In general, there are two pathways of NF-κB consisting of distinct 
stimuli, intermediate pathway mediators, and NF-κB components, respectively designated as 
canonical and non-canonical NF-κB pathways (Figure 1.10). In the past 25 years, NF-κB has 
been intensively studied as a result of its importance in immunology and cancer biology 
(Hayden and Ghosh, 2012). To date, about 5000 review papers are publically available. This 
has made a comprehensive review on all aspects of NF-κB unfeasible. Hence, in this thesis, I 
will only give a brief introduction of NF-κB pathways and focus primarily on the oncogenic 




























1.3.1.1 Canonical NF-κB pathway 
 
Canonical NF-κB pathway is more widely studied as compared to the non-canonical 
NF-κB pathway. It was suggested that the canonical NF-κB pathway is defined by the 
involvement of NEMO (also known as IKKγ) in the activation of NF-κB transcription factors 
(Shih et al., 2011). This pathway could be activated by a wide variety of stimuli including 
proinflammatory cytokines (e.g., TNFα and IL1), pathogen associated molecular patterns 
(PAMPs) (e.g., LPS), and cellular stress (e.g., DNA damage) (Pahl, 1999). NF-κB is normally 
expressed, dimerized, and sequestered by Inhibitor of κB (IκB) in the cytoplasm, poised for 
activation by appropriate stimuli. Upon stimulation, the IKK complex containing NEMO, 
IKKα, and IKKβ would be activated by phosphorylation. The phosphorylated IKKβ would in 
turn phosphorylate IκB, and lead to proteosomal-dependent degradation of the latter. In the 
canonical pathway, IκBα, the most common isoform of the IκB family, is predominantly 
Figure 1.10 Canonical and non-canonical pathways of NF-κB. Adapted from (Jost 





associated with RelA/p50 dimer prior to stimulation. After IκB is degraded, the transcription 
factors would then translocate into the nucleus to turn on specific gene transcription.  In some 
studies, Rel was shown to have overlapping role as RelA, and is also implicated in canonical 
pathway (Gilmore, 2006).  
A large cohort of target genes is regulated by RelA (Pahl, 1999), the transcriptional 
output of the target genes is fine-tuned by the type of stimuli, combinations of RelA dimer, 
and cellular context. In general, the canonical NF-κB pathway is recognized to play crucial 
roles in mounting innate immune response. Upon stimulation, a large number of genes would 
be upregulated, for instance cytokines (e.g., IL8, IL6, TNFα, and LTβ), adhesion molecules 
(e.g., ICAM1 and VCAM1), acute phase protein (e.g., SAA), and inducible enzymes (e.g., 
COX2). The elevation of these secretory molecules would recruit more inflammatory 
leukocytes to the site where the NF-κB pathway is stimulated. 
Under normal condition, the activation of canonical NF-κB pathway is well-
controlled temporally. After acute activation of RelA-containing dimer, several events would 
occur to quench and terminate NF-κB signaling. The negative feedback mechanisms include: 
(i) expression of IκB that could relocalize RelA-dimer back to the cytoplasm; (ii) expression 
of TNFΑIP3 that could inhibit further activation of IKK; (iii) phosphorylation of RelA 
mediated by IKK in the nucleus could lead to the ubiquitination and degradation of RelA by 
E3 ligase PIAS1 (Shih et al., 2011). 
1.3.1.2 Non-canonical NF-κB pathway 
 
Non-canonical NF-κB pathway is demonstrated to be activated by a subset of TNF 
superfamily receptors (TNFSFRs), which includes lymphotoxin β receptor (LTβR), CD40 and 
B-cell activating factor receptor (BAFFR) (Razani et al., 2011). Upon stimulation, cellular 
inhibitor of apoptosis (cIAP1 and cIAP2) would be activated, causing the degradation of 





stabilized and able to phosphorylate and activate IKKα specifically. The activated IKKα 
would in turn phosphorylate and partially degrade p100 to produce p52, which preferentially 
binds to RelB. The intact p100 functions similarly as IκB to keep RelB in the cytoplasm by 
physical interaction through ankyrin repeats domain. After partial degradation, RelB/p52 
dimer is released from sequestration and move to the nucleus to initiate gene transcription. 
The target genes regulated under non-canonical NF-κB pathway are less-well studied. 
The physiological importance of these pathways was mainly demonstrated in mice with 
genetically modified NIK, IKKα, and p100 (Razani et al., 2011). It was shown that mice with 
disrupted non-canonical NF-κB signaling would manifest developmental defects of secondary 
immune organs like lymph nodes and spleen (Futterer et al., 1998), as well as B-cells 
development (Weih et al., 2001) and osteoclast differentiation (Vaira et al., 2008). 
Unlike canonical NF-κB pathway, the activation of non-canonical NF-κB pathway is 
relatively slower but more sustained. However, little was known about the termination of this 
pathway. A recent study has shed light on this topic. It was found that the activated IKKα 
could feedback to phosphorylate and destabilize NIK, thereby regulating the activation of 






1.3.2 NF-κB and cancers 
 
NF-κB pathway has been implicated in multiple solid tumors as well as leukemia 
(Aggarwal et al., 2006; Jost and Ruland, 2007; Karin and Greten, 2005; Lee et al., 2009). NF-
κB is reported to have ability to modulate the expression of tumor suppressor genes and 
oncogenes. It was thought that the silencing of key tumor suppressors like p53 and PTEN has 
skewed NF-κB activity to be pro-oncogenic (Mayo et al., 2002; Rocha et al., 2003). Up till 
now, the link of NF-κB to cancer has been well established. A couple of recent review articles 
have even suggested NF-κB-related inflammation as one of the hallmarks of cancer (Colotta 
et al., 2009; Hanahan and Weinberg, 2011).  
1.3.2.1 Oncogenic functions of NF-κB 
 
The oncogenic roles of NF-κB are mainly dependent on its ability to upregulate a 
large number of oncogenes involved in multiple aspects of oncogenesis (Jost and Ruland, 
2007). The participation of NF-κB in oncogenesis is considerably extensive, from the basic 
features of tumor cells like enhanced cell proliferation, biological processes involved in 
advanced cancer progression like angiogenesis and metastasis, and even resistance to 
adjuvant therapy through promoting cancer cell survival. 
Here, I provide an introduction on the series of events that describes how NF-κB 
could participate in the whole course of cancer progression (Perkins, 2012). Several cell cycle 
regulators are regulated by NF-κB such as Cyclin D1, Cyclin E, and CDK2 (Pahl, 1999). The 
upregulation of these genes enables cells to enter cell cycle progression and induces cell 
proliferation. Dysregulated expression of these genes would thus contribute to uncontrolled 
tumor growth. When tumor mass grows to a certain size, the oxygen supply to the tumor cells 
would become insufficient and enter a condition called hypoxia. As the result, NF-κB is 
activated by hypoxic elements released by the tumor cells (e.g., HIFα), angiogenic genes (e.g., 





κB could also upregulate the expression of multiple pro-inflammatory cytokines such as 
TNFα, IL6, IL8, and IL1, which when released would attract tumor-infiltrating leukocytes. 
These leukocytes would further aggravate angiogenesis and promote cancer progression. The 
elevated expressions of adhesion molecules like ICAM1 and VCAM1 induced by NF-κB 
have been implicated in increased motility of cancer cells. In addition, NF-κB could also 
promote the expression of MMPs and uPA that helps to degrade extracellular matrix and 
facilitate invasion of cancer cells. Importantly, NF-κB regulates numerous pro-survival genes 
like BCL2, BCL-XL, survivin, and BIRC3, which play critical roles in cancer cells survival 
especially in conferring chemoressistance in response to anti-cancer adjuvant therapy. 
1.3.2.2 Constitutive activation of NF-κB in cancers 
 
Under normal physiological conditions, NF-κB transcription factors are tightly 
regulated and sequestered in the cytoplasm. In cancers, however, NF-κB is observed to be 
constitutively active from the nuclear localization of the transcription factors observed in 
histoimmunochemistry staining of cancer tissue (Aggarwal et al., 2006; Lee et al., 2009). It is 
believed that constitutive activation of NF-κB cause persistent upregulation of pro-oncogenic 
target genes, leading to tumor progression. 
Multiple mechanisms have been proposed to be accountable for constitutive 
activation of NF-κB in cancers. For instance, overexpression of upstream kinases like NIK 
and LTβR (Dhawan et al., 2008; Yamamoto et al., 2010) as well as the secretion of activating 
cytokines like TNFα and IL1β by tumor-associated leukocytes in tumor microenvironment 
would lead to continued NF-κB activation (Goldberg and Schwertfeger, 2010). Genetic DNA 
amplification of Rel in lymphoma is also proposed to be one of the causes of constitutive NF-
κB activation (Barth et al., 2003). In additional, a shorten IκB half-life and mutations of IκB 
were also observed in B-cell lymphoma and Hodgkin lymphoma respectively (Sethi et al., 
2008), would also release NF-κB from inhibition and lead to constitutively activation of NF-





1.3.2.3 Targeting NF-κB in cancers 
 
Due to the extensive involvement of NF-κB in cancer progression, this pathway 
served as an attractive therapeutic target (Aggarwal and Gehlot, 2009). To date, more than 
700 inhibitors of NF-κB pathway have been identified (Gupta et al., 2010). These inhibitors 
encompass natural products, synthetic small molecules, and small DNA/RNA and peptides. 
NF-κB pathway can be targeted by these inhibitors at different unique components of the 
pathway (Gupta et al., 2010; Perkins, 2012; Prasad et al., 2010), for example: (i) IKK activity 
and IκB phosphorylation (e.g., sulindac and pomegranate extract); (ii) NF-κB nuclear 
translocation (e.g., SN50 and epicatechin); (iii) NF-κB post-translational modification (e.g., 
resveratrol and gallic acid); and NF-κB DNA binding (e.g., DHMEQ and sesquiterpene 
lactones). 
Although enormous number of NF-κB inhibitors has been developed, not many of 
them were evaluated in terms of biological activity in vivo and cytotoxic effects. Among those 
inhibitors that were approved by US Food and Drug Administration (FDA), many of them are 
originally developed for other protein targets and in turn discovered to inhibit NF-κB pathway. 
These inhibitors include aspirin, which was intentionally used for inhibiting COX1/2 activity, 
but was later reported to inhibit IKKβ activity (Yin et al., 1998); simvastatin, which was 
initially used for controlling elevated cholesterol, was later shown to inhibit DNA binding of 
NF-κB (Lee et al., 2007). On the other hand, bortezomib, a proteasome inhibitor developed in 
attempt to inhibit NF-κB pathway by blocking IκB degradation, has obtained accelerated 
approval from FDA and was used for treatment of multiple myeloma (Kwak et al., 2011). 
However, it was found that bortezomib has a wider range of targets and the exact mechanism 
of its effectiveness is not well-defined (Yang et al., 2009b). 
NF-κB is an essential player regulating normal physiological functions like immune 
responses and cellular homeostasis. Therefore, a major challenge for the development of NF-





activity of NF-κB in cancer cells. Nevertheless, the use of aspirin (anti-inflammatory agent) in 
preventing colorectal cancer in high risk individuals has demonstrated the potential of 






1.3.3 NF-κB in breast cancer 
 
Similar to other cancers, NF-κB was also found to be constitutively active in breast 
cancer (Bhat-Nakshatri et al., 2002; Nakshatri et al., 1997). However, the mechanism 
underlying constitutive activation of NF-κB is not well elucidated. Two independent studies 
have indicated that transient activation of SRC or MEK/ERK pathway could initiate NF-κB 
activation and the subsequent feed forward signaling for self-sustainable NF-κB constitutive 
activity (Iliopoulos et al., 2009; Rokavec et al., 2012). Noteworthy, IL6 was implicated to 
have a crucial role in the feed forward maintenance of NF-κB signaling in breast cancer. 
More than a decade ago, NF-κB was implicated to play a role in driving breast cancer 
progression (Nakshatri et al., 1997). It was found that when breast cancer progresses from a 
hormonal-dependent, non-metastatic form to higher grade hormonal-independent and 
metastatic form, the activity of NF-κB would be elevated. In addition, constitutive activation 
of NF-κB is reported to occur more frequently in basal-like breast cancer (BLBC) cells, which 
are mostly ER-negative (Gionet et al., 2009). Indeed, a recent study showed that ectopic 
expression of ER in ER-negative breast cancer cells could suppress the expression of RelB 
(Wang et al., 2007). On the other hand, RelB was also found to be able to suppress ER 
expression (Wang et al., 2009). These findings highlight the antagonistic roles of ER and NF-
κB, particularly on the non-canonical pathway. 
Consistent with the findings showing constitutive activation of NF-κB in advanced 
metastatic breast cancer, multiple target genes of NF-κB were also reported to enhance the 
invasiveness and metastatic potential of breast cancer cells. For instance, IL8 was shown to 
increase breast cancer cells in vitro and in vivo (Wu et al., 2008) and is elevated in serum of 
patients experiencing breast cancer cell dissemination (Benoy et al., 2004). Another NF-κB 
target, TNFα, was demonstrated to increase cell invasion when applied to breast cancer cell 
lines (Cho et al., 2009; Kim et al., 2008). Last but not least, IL6 was revealed to induce breast 





(Knupfer and Preiss, 2007). Furthermore, IL6 and IL8 was implicated in the maintenance of 
breast cancer stem cells (Iliopoulos et al., 2009; Iliopoulos et al., 2011; Liu and Wicha, 2010; 
Schafer and Brugge, 2007). IL6 (Conze et al., 2001) and BIRC3 (Hernandez-Vargas et al., 






1.4 Aims and Objectives of Study 
 
Basal-like breast cancer (BLBC) cells are often triple-negative, which represents a 
subset of breast cancer that lacks the expression or cell surface receptors, ER, PR, and HER2. 
This property has rendered BLBC irresponsive to receptor-targeted therapy. Furthermore, the 
poor prognosis of BLBC patients has made it a focus of research in order to develop a better 
approach in treating this subtype of breast cancer. The aim of this study is to dissect the role 
of EZH2 in BLBC, due to its elevated expression in this breast cancer subtype. By using 
small-interfering RNA to deplete EZH2 in BLBC model cell lines, we identified the crosstalk 
between EZH2 and NF-κB pathway in BLBC. Similar to the case of EZH2, NF-κB was found 
to be constitutively active in BLBC. Therefore, we sought to delineate the underlying 
mechanism of EZH2 regulation on NF-κB activity in BLBC as well as the clinical relevance 
of such regulation. 
In addition, we were interested to study the function of EZH2in luminal breast cancer, 
which harbors high expression of EZH2 aibeit a lower level than BLBC. On the contrary, 
luminal breast cancer was known to have low activity of NF-κB signaling. Hence, we aimed 
to further understand the potential crosstalk between EZH2 and NF-κB in luminal breast 
cancer. 
Taken together, different functions of EZH2 would be dissected in relation to the 



































2.1 Cell culture and treatments 
 
MDA-MB-231, BT549, MCF7, and T47D cell lines were obtained from American Type 
Culture Collection (Manassas, VA). The normal breast epithelial cell line, HMEC, was a 
generous gift from Dr. W.C. Hahn of Dana-Farber Cancer Institute. MDA-MB-231, 
BT549, MCF7, and T47D cell lines were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum and 5000U/mL penicillin/streptomycin 
(Invitrogen). HMEC normal breast epithelial cell line was grown in DMEM/F12 
supplemented with 5% horse serum, 20ng/ml EGF, 0.5mg/ml hydrocortisone, 100ng/ml 
cholera toxin, 10µg/ml insulin, and penicillin/streptomycin (Invitrogen). All cells were 
maintained in logarithmic monolayer growth in 75cm2 flask at 37°C with 5% CO2 in a 
humidified atmosphere. For ChIP and co-immunoprecipitation assays, cells were treated with 
10ng/ml TNFα (Calbiochem) for 2 hours prior harvest. For quantitative RT-PCR assays and 
Microarray gene expression analyses, cells were treated with 10ng/ml TNFα for 4 hours prior 
harvest.  
2.2 Cryopreservation of cell lines 
 
All cell lines were grown and maintained for less than 30 times passages. After which, frozen 
cells with lower passage number from liquid nitrogen tank (-196°C) were thawed at 37°C and 
neutralized with 6ml complete media. Cells were spun down at 800rpm for 5 minutes and cell 
pellets were resuspended with fresh complete media and seeded into T25 flasks. Cells were 
allowed to stabilize for 1 week before experiments were conducted. To freeze down cells for 
cryogenic preservation, cells were trypsinized and spun down at 100rpm for 3 minutes. Cell 
pellets were then resuspended with freezing media (For HMECs: 90% culture media and 10% 
DMSO; for other cell lines: 90% FBS and 10% DMSO) and aliquoted 1ml of 1x106 cells into 





cylinder (NALGENE) filled with 99% iso-propanol and kept at 80°C freezer. After 24 hours 
of incubation, cells were then transferred to liquid nitrogen tank. 
2.3 Transfection of Small interfering RNA 
 
siRNA and plasmids transfections were conducted using Lipofectamine RNAiMax 
(Invitrogen) and FugeneHD (Roche Applied Science), respectively according to the 
manufacturer’s instructions. For siRNA transfection, 5ul of siRNA (20uM) and 4ul of 
RNAiMax were separately diluted into 100ul basic media. After 5 minutes of incubation, the 
two diluents were mixed together and incubate for another 20 minutes before adding the 
transfection mixture into 800ul complete medium-containing 6 well-plate, which was seeded 
with monolayer cells 18 hours prior transfection. The working concentration of siRNA was 
100nM. The transfected cells were either being trypsinized 24 hours post transfection and 
reseeded for downstream assays or changed media 24 hours post transfection and further 
incubated until the time of harvesting. For transient overexpression plasmid transfection, 
Target-specific siRNA and non-targeting control siRNA were purchased from 1st Base 
Singapore with the following target sequences: EZH2 siRNA: 5’-
GACUCUGAAUGCAGUUGCU-3'. EZH2 siRNA 5’-UTR; 5’-
CGGUGGGACUCAGAAGGCA-3’; RelA siRNA: 5’-GCCCUAUCCCUUUACGUCA-3’; 
RelB siRNA: 5’-GCCCGUCUAUGACAAGAAA-3’; ERα. siRNA: 5'-
UCAUCGCAUUCCUUGCAAA-3'. 
2.4 Transfections of transient overexpression plasmids 
 
pcDNA3-RelA and RelB were purchased from Addgene. pcDNA4-EZH2 wild type and SET 
domain deletion plasmid have been described previously (Wu et al., 2011). To perform 
transient overexpression for exogeneous co-immunoprecipitation, 5ug of pcDNA3-RelA, 5ug 
of pcDNA3-RelB, and 5ug of pcDNA4/pcDNA4-EZH2/pcDNA-EZH2-SET∆ were diluted in 
500ul basic medium and incubate for 5 minutes. 45ul of FugeneHD was then added (1ug 





was then added into 4.5ml complete medium-containing 10cm petridish, which was seeded 
with monolayer cells 18 hours prior transfection. The media of the transfected cells was 
changed with fresh complete DMEM 24 hours post transfection and samples were harvested 
72 hours post transfection.  
2.5 Generation of stable overexpression cell lines 
 
Target genes from their respective transient expression plasmids were amplified by PCR and 
subcloned into the pMN GFP/IRES retroviral expression vector (obtained from Dr. Linda 
Penn’s lab). To generate stable overexpression cell lines, 4ug of plasmids and 10ul of 
Lipofectamine 2000 were separately diluted into 100ul basic media. After 5 minutes of 
incubation, the two diluents were mixed together and incubate for another 20 minutes before 
adding the transfection mixture into 800ul OptiMEM-containing 6 well-plate (collagen I 
coated, BIOCOAT from BD), which was seeded with monolayer platinum-A retroviral 
packaging cells (CELL BIOLAB, INC., San Diego, CA) 18 hours prior transfection. After 6 
hours of incubation, transfection media were replaced by 2.5ml fresh complete DMEM. After 
48 hours post transfection, conditioned media from the transfected PlatA cells, which now 
contained retroviruses packaged with our target genes, were harvested and filtered through 
0.45um filter unit. Destination cells were seeded in 6-well plate 24 hours prior viral infection. 
2ml conditioned media were then added to 1ml complete media containing 3ul of 8ug/ml 
polybrene in the destination cells, followed by centrifugation at 1800rpm for 90 minutes. 48 
hours post viral infection, destination cells were trypsinized and grew in culturing flasks. 
Viral infected cells were sorted based on GFP over-expression.  
2.6 RNA extraction 
 
Cell pellets were collected by harvesting monolayer cells by trypsinization. 1ml Trizol 
(Invitrogen) was added to lyse the cell pellet, followed by the addition of 200ul chloroform 





the cell contents. After centrifugation, the top liquid phase containing RNA was transferred to 
fresh eppendorf tube followed by addition of 70% ethanol. To purify RNA, RNeasy mini kit 
(Qiagen) was used. Briefly, the samples were transferred to the column to allow RNA binding 
and flow through were accelerated by centrifugation at 10krpm for 30 seconds. Columns were 
washed once with 750ul RW1 buffer and twice with 500ul RPE buffer. Finally, RNA was 
eluted with 40ul RNAse-free water. RNA concentration and purity were assessed using 
NAnodrop ND-1000. 
2.7 cDNA conversion and Quantitative real-time PCR (RT-PCR) 
 
RNA samples were reverse transcribed and converted to single-stranded complementary 
DNA (cDNA) using High Capacity cDNA Reverse Transcription Kits (Applied Biosystems). 
In brief, 750ng of RNA samples were diluted in 25ul nuclease-free water and added with 25ul 
of master mix containing 5ul RT buffer, 5ul random primers, 2ul dNTP mix, and 2.5ul 
MultiScribeTM reverse transcriptase and 10.5ul nuclease-free water. The reaction mix was 
then subjected to PCR in thermo cycler running for 10 minutes at 25ºC followed by 2 hours at 
37ºC. To perform quantitative real-time PCR, 0.44ul of cDNA samples (15ng/ul) were added 
together with 0.4ul gene-specific primer mix (10uM) to 5ul of 2X master mix from KAPA 
SYBR® FAST qPCR Kits (Kapa Biosystems) and top-up to 10ul with nuclease-free water. 
Finally, the reaction mix was amplified and quantified with PRISM 7900 Sequence Detection 
System (Applied Biosystems). 
2.8 Microarray Gene Expression Profiling and Analyses 
 
The microarray hybridization was performed in using the Illumina Gene Expression Sentrix 
BeadChip HumanRef-8_V2 (San Diego, CA) following manufacturer’s protocol. Briefly, 
500ng RNA samples were reverse transcribed into cDNA and further processed into double-
stranded cDNA. After purification of cDNA, biotinylated cRNA was generated and further 
purified. The biotiylated cRNA was hybridized onto BeadChip and stained with streptavidin-





images were stored with barcodes indicated. The scanned images were processed using 
Illumina GenomeStudioTM and the generated data were imported into GeneSpringGXTM 
(Agilent Technologies) for further analysis. Gene expression data were deposited at NCBI 
Gene Expression Omnibus (GEO) repository database under the accession number GSE30670. 
Using GeneSpringGX, the data were analyzed by selecting Illumina single color as 
experimental type and signals were normalized to median expression. Fold changes were 
analyzed by pairwise comparisons to appropriate controls. To generate heatmaps, median-
normalized data represented in log2 values were processed by Cluster and visualized by 
Treeview softwares (Eisen, 1998).  
2.9 Gene Ontology analysis 
 
Genes that were expressed with two-fold differences after EZH2 depletion in MB231 were 
separated into upregulated and downregulated genesets. The two genesets were then imported 
into Ingenuity Pathway Analyses (IPA) software for gene ontology analysis. From the 
analysis, signaling pathways and biological functions enriched in the imported genesets were 
obtained. Genes that appeared in the analyzed geneset and enriched in the biological function 
was indicated in the signalling network exported from IPA. 
2.10 Protein extraction 
 
Cell pellets were collected by harvesting monolayer cells through trypsinization. For total 
protein extraction, cell pellets were then resuspended with 30ul to 40ul 
radioimmunoprecipitation assay lysis buffer (50mM Tris-HCl pH7.4, 1mM EDTA, 150mM 
NaCl, 1% Igepal CA630, 0.5% sodium deoxycholate, 1mM Na2VO4, 20mM NaF, 1mM 
PMSF, and Complete protease inhibitor (Roche)). Samples were incubated on ice for 30 
minutes, vortexed for 15 seconds every 5 minutes. Subsequently, samples were sonicated 
twice for 5 seconds followed by centrifugation at 13.2krpm for 15 minutes at 4ºC. 
Supernatant was transferred to fresh eppendorf tubes and protein concentration was estimated 





measured using Tecan XfluorTM software. Nuclear and cytoplasmic fractionation was 
conducted using NE-PER Fractionation Kit (Pierce) following manufacturer’s protocol.  
2.11 Western Blotting 
 
Protein samples (20-30ug) were separated by 8% or 10% SDS-PAGE gel and subsequently 
transferred onto PVDF membrane (Millipore) using Trans-Blot SD Semi-Dry transfer cell 
(Bio-Rad). Membranes with immobilized proteins were blocked with 5% non-fat milk (Bio-
Rad) for 30 minutes followed by primary antibodies for 1 hour and HRP-conjugated 
secondary antibodies for 45 minutes. Membranes were incubated with chemoluminescent 
ECL Substrate Kit (Amersham) and signals were detected using Kodak films. Anti-EZH2 
(CS-3147) and ERα (CS-2512) was purchased from Cell Signaling. Anti-RelA (sc-8008) and 
anti-RelB (sc-48366) were obtained from Santa Cruz, anti-SuZ12 (39357) was obtained from 
Active Motif, anti-trimethylated H3K27 (07–449), anti-H3 (06–599), were purchased from 
Upstate. Anti-Myc and anti-actin were purchased from Roche Applied Science and Sigma-
Aldrich, respectively.  
2.12 Co-immunoprecipitation (co-IP) 
 
50ug nuclear protein lysates were diluted with 500ul IP lysis buffer and precleared with 30ul 
Protein A Sepharose beads (Roche) for 4 hours. Samples were centrifuged at 12krcf for 20 
seconds and supernatants were transferred to fresh eppendorf tubes. 2ug of specific primary 
antibodies were added and samples were rotated overnight at 4ºC. 25ul Protein A beads were 
added the next day morning and further incubated for 1 hour. Beads that now contained 
immunoprecipitated samples were washed once with IP Lysis buffer, once with Washing 
buffer 2 and once with Washing buffer 3. Immunoprecipitates were eluted with SDS loading 
buffer and analysed with Western Blotting. For endogeneous co-IP, less stringent 
lysis/washing buffers were used: IP Lysis buffer (Triton X-100: 1%; NaCl: 150 mM; 20 mM 
Tris-HCl pH8.0); Washing Buffer 2/3 (50mM Tris-HCl pH7.4; NaCl 150mM); for 





Tris-HCl pH7.4, 150mM NaCl, 0.5% sodium deoxycholate, 0.5% Igepal CA630); Washing 
buffer 2 (50mM Tris-HCl pH7.4, 500mM NaCl, 0.05% sodium deoxycholate, 0.1% Igepal 
CA630); Washing buffer 3 (50mM Tris-HCl pH7.4, 0.05% sodium deoxycholate, 0.1% 
Igepal CA630). Anti-EZH2 (#39901, Active Motif), anti-RelA (sc-109), anti-RelB (sc-226), 
anti-ERα (SC-543) or a non-specific IgG (sc-2027) was used in the co-IP assay. Densitometry 
was performed using UN-SCAN IT gelTM V6.1 software (Silk Scientific), following 
manufacturer’s instruction. 
2.13 Chromatin Immunoprecipitation (ChIP) and Sequential ChIP 
 
Cells were expanded in 15cm petridish. To harvest for ChIP assay, cells were fixed with 3.7% 
paraformaldehyde for 20 minutes with gentle shaking followed by neutralization with 2ml 2M 
glycine for 5 minutes with gentle shaking. Fixed cells were washed twice with 10ml cold PBS 
and subsequently harvested by scrapping. Cell pellets were then lysed with 500ul SDS lysis 
buffer (1%SDS, 5mM EDTA, 50mM TrisHCl pH8) and sonicated for 6.5 minutes (30 
seconds pulse on and 30 seconds pulse off) followed by centrifugation at 13.2krpm for 10 
minutes. Supernatants were then transferred to 15ml Falcon tubes and top-up with Dilution 
buffer (1% TritonX100, 2mM EDTA, 20mM TrisHCl pH8, 150mM NaCl) to 3ml. Samples 
were then precleared with 210ul BSA blocked Protein A beads (Zymed) and 1ug normal IgG 
for 4 hours with rotation at 4ºC. Pre-cleared chromatin was immunoprecipitated with 10ug 
specific primary antibodies and rotated overnight at 4ºC. 80ul Protein A beads were added the 
next day morning and further incubated for 1 hour. Beads were then washed ten minutes each, 
once with 5ml TSEI buffer (0.1% NP40, 1% TritonX100, 2mM EDTA, 20mM TrisHCl pH8, 
150mM NaCl), once with 5ml TSEII (0.1% SDS, 1% TritonX100, 2mM EDTA, 20mM 
TrisHCl pH8, 500mM NaCl), once with 5ml Buffer III (0.25M LiCl, 1% NP40, 1% sodium 
deoxycholate, 1mM EDTA, 10mM TrisHCl pH8), and once with 5ml TE Buffer (2mM 
EDTA, 10mM TrisHCl pH8). Immunoprecipitated chromatins were eluted with 240ul SDS 
Elution Buffer (1%SDS, 10mM EDTA, 50mM TrisHCl pH8) and shaked at 65ºC for 30 





at 65ºC. Purification of immunoprecipitated DNA was performed using PCR purification kit 
(Qiagen) following manufacturer’s protocol. The immunoprecipitated DNA was quantitated 
by real-time quantitative PCR using KAPA SyBr Fast qPCR kit (KAPA Biosystems). The 
enrichment of specific genomic regions was assessed relative to the input DNA followed by 
normalization to the respective control IgG values. Primer sequences were listed in the table 
below. Anti-EZH2 (#39901, Active Motif), anti-RelA (sc-109), anti-RelB (sc-226), Anti-
H3K27me3 (Upstate 07-449), anti-ERα (SC-543) or a non-specific rabbit IgG (sc-2027) was 
used in the ChIP assay. Primer sequences were listed in the table below. 
Sequential ChIP was performed with similar procedures as ChIP assay except that first ChIP 
antibodies were crosslinked to Protein A beads with disuccinimidyl suberate (DSS) (Pierce) 
prior to the first immunoprecipitation process. Immunoprecipitated chromatin from the first 
IP was eluted with SDS elution buffer at 37ºC for 45 minutes. The eluate was then subjected 
to second IP using the same protocol as mentioned above. 
2.14 Recombinant Protein Expression 
RelA and RelB genes were subcloned into pDEST-HisMBP vector and EZH2 gene was 
subcloned into pDEST565 vector. The plasmids were then transformed into BL21 bacteria 
strain and the protein expression was induced by 0.4uM IPTG for 16 hours at 23˚C. Bacteria 
cultures were spun down 9krpm for 7 minutes, and resuspended with 30ml Lysis buffer (MBP 
lysis/washing buffer: 50mM Tris-HCl pH8, 0.1% β-ME, 100mM NaCl, 0.1% Triton-X100, 
protease inhibitors; GST Lysis buffer: PBS added with protease inhibitors). PBS 
complemented with CompleteTM protease inhibitors. After a cycle of freeze-thaw, bacteria 
lysates were sonicated for 30 minutes (3 seconds pulse on, 2 seconds pulse off). Protein 
lysates were obtained by centrifugation at 20krpm for 1 hour at 4˚C. The MBP-tagged 
recombinant proteins were then purified using amylose resin (Biolabs) and eluted with MBP 
Elution buffer (50mM Tris-HCl pH8, 0.1% β-ME, 100mM NaCl, 0.1% Triton-X100, 10mM 
maltose, protease inhibitors); whereas the GST-tagged recombinant proteins were purified 





Tris-HCl, pH8.0, 150mM NaCl, 10mM reduced glutathione, 10mM DTT, 0.1% Triton X100, 
and protease inhibitors). Protein concentrations were determined using DC Protein Assay 
(Bio-Rad). 
2.15 In vitro pull down and re-IP 
50ug of MBP or MBP-tagged RelA or RelB was respectively incubated with 50ug GST-
tagged EZH2 and 20ul of amylose resin. The pulls down reactions were incubated for 16 
hours at 4˚C.  The beads were then washed with MBP lysis/washing buffer (50mM Tris-HCl 
pH8, 0.1% β-ME, 100mM NaCl, 0.1% Triton-X100) and finally eluted using SDS lysis buffer 
and (Cell Signaling) followed by Western Blot analysis. For re-immunoprecipitation, MBP-
tagged RelA and RelB were treated with TEV protease for 1 hour at room temperature. Next, 
12ug RelA and RelB were incubated for 16 hours at 4˚ C with 5ug GST or GST -EZH2, which 
was bound to 20ul glutathione sepharose beads. The beads were then washed as described in 
co-IP assay. Pulled down complexes were eluted with GST elution buffer. The eluted protein 
complexes were then subjected to co-IP assay as described earlier.    
2.16 Transwell Invasion Assay 
 
24-well FluorBlok transwell inserts (#351152, BD Biosciences) with a pore size of 8um were 
pre-coated with 80ul of growth factor-reduced matrigel (500ug/ml) (#356231, BD 
Biosciences) for 5 hours at 37˚C. 5x104 MDA-MB-231 depleted of EZH2, RelA, and/or RelB 
were seeded in each insert with 200ul DMEM containing 0.5% FBS. 750ul DMEM 
supplemented with 0.5% FBS and 100ng/ml EGF was added outside the chamber as 
chemoattractant. Invaded cells were fixed after 48 hours of incubation by using 3.7% 
formaldehyde and stained with 25ug/ml propidium iodide (Sigma). 10 fields per inserts were 






2.17 3D Matrigel Anchorage-Independent Growth Assay 
 
8-well chamber slides (#384118, BD Biosciences) were pre-coated with 45ul of 7.6mg/ml 
growth factor-reduced matrigel (#356231, BD Biosciences) for 30 minutes at 37˚C. 5x10 3 
MDA-MB-231 depleted with EZH2, RelA, and/or RelB were seeded in each well with 400ul 
DMEM containing 10% FBS and 150ug/ml matrigel. Media was replaced with fresh media 
before phase contrast images were captured for 8 days at 4 days interval.   
2.18 Dual Luciferase Reporter Assay 
 
NF-κB-specific reporter plasmid pGL4.32, its negative control pGL4.15, and pRL-null were 
purchased from Promega. During transfection, 500ng pGL4/pGL4-NF-κB and 20ng pRL-null 
were diluted in 50ul basic media. After 5 minutes of incubation, 2.6ul FugeneHD was added 
and further incubated for 20 minutes. The transfection mixtures were then added into 400ul 
complete medium-containing 24-well plate, which was seeded with monolayer cells 18 hours 
prior transfection. The media of the transfected cells was changed with fresh complete media 
24 hours post transfection. Cells were harvested 48 hours post transfection and luciferase 
activity was detected using the Dual Luciferase system (Promega) following manufacturer’s 
protocol. For rescue assay, similar transfection method was adopted except Lipofectamine 
2000 was used as the transfection reagent to transfect plasmids and siRNA simultaneously. 
To analyze luciferase activity, Firefly signals of pGL4/pGL4-NF-κB were normalized to 
Renilla signals of pRL-null in respective samples. pGL4-NF-κB/pRL-null ratio were further 
normalized to pGL4/pRL-null ratio to obtain normalized values corrected for the changes of 






2.19 Clinical Datasets and Survival Analysis 
 
The expression data for the 54 breast cancer cell lines was described previously (Neve et al., 
2006). The breast cancer data set from Farmer and Netherlands cohort with relevant clinical 
information has been described previously (Bos et al., 2009; Farmer et al., 2005). The 
EZH2/RelA/RelB co-regulated gene subset was used to classify breast cancer patients into 
higher expression or lower expression groups based on the mean of the expression of the 
subset of genes. Using the survival event status and time information, we computed the 
survival association of expression status (high/low expression) using Cox-Proportional 
Hazards model implementation (coxph) available in R-library “survival”. Kaplan-Meier 
survival analysis was used for the analysis of clinical outcome.  
2.20 Statistical Analysis 
 
Statistical analyses of the bar graphs in this study were performed using Prism (GraphPad 
software Inc.). Student t-tests were carried out on triplicated experimental readings to 



























3.1 EZH2 Positively Regulates NF-κB-Mediated Gene Network in 
Aggressive BLBC Cells  
 
To gain mechanistic insights into the role of EZH2 in aggressive breast cancers, we 
sought to determine EZH2-dependent gene expression in basal-like breast cancer cells. To 
this end, we depleted EZH2 by small interference RNA (siRNA) in a widely used BLBC cell 
line, MDA-MB-231 (hereafter named MB231) cells and performed gene expression profiling 
using Illumina 24K human BeadArray-V2. Gene expression analysis led to identification of 
836 genes that were differentially expressed upon EZH2 depletion (using two-fold cut-off, 
p<0.01), including 391 genes up-regulated and 445 genes down-regulated, respectively (Table 
S1). The great number of downregulated genes indicates with interest that in addition to the 
well-known function of EZH2 in gene repression, EZH2 may also have a similar capacity in 
promoting gene activation, even though it could be an indirect effect. To gain further insights 
into the biological functions of EZH2, we performed Ingenuity Pathway Analysis (IPA) with 
the two separate groups of genes and identified several gene networks that were highly 
enriched in EZH2 regulated genesets (Figure 3.1). Most networks identified were correlated 
with the known transcriptional repression functions of EZH2 such as cell cycle, cell death, 
cellular movement, and developments. Interestingly, inflammatory response was one network 
that was highly enriched only in EZH2 knockdown downregulated genesets (Figure 3.1B).  
From the introduction, we know that inflammatory responses are mainly mediated by 
NF-κB transcription factors. As expected, the illustrated inflammatory network exported from 
IPA displayed a well interconnected regulatory system with NF-κB as a central node (Figure 
3.2A). This suggested that NF-κB might be the key modulator of the inflammatory response 
under the regulation of EZH2. 36 genes enriched in the inflammatory network were further 
illustrated in a heatmap representing their expression profile after EZH2 depletion in MB231 
(Figure 3.2B). From the heatmap, we noticed that many well-known NF-κB target genes such 





the triplicate microarray results). This observation raised a possibility that EZH2 may 
positively regulate NF-κB-mediated inflammatory gene network in MB231 cells. 
 
EZH2 knockdown upregulated geneset 
Top network functions  Score  
Infection Mechanism, Cardiovascular System Development and function, 
Organismal Development  42 
Cell Death, Cell Signaling, Cellular Assembly and Organization 31  
Cellular Movement, Dermatological Diseases and Conditions, Genetic 
Disorder  30 
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry  29  
Cardiovascular Disease, Cardiovascular System Development and 
Function, Organismal Development  28 
 
EZH2 knockdown downregulated geneset 
Top network functions  Score  
Cell Cycle, Cancer, Genetic Disorder  38  
Cell Death, Cellular Growth and Proliferation, Cell Cycle  36  
Inflammatory Response, Cellular movement, Hematopoiesis  31  
Organismal Injury and Abnormalities, Cancer, Gastrointestinal Disease  31  
Cell Cycle, Connective Tissue Development and Function, Organismal 











Figure 3.1 Ingenuity pathway analyses of genesets regulated by EZH2 in MB231 
A. Ingenuity Pathways Analysis (IPA) showing the top gene networks enriched 
in upregulated genes following EZH2 depletion in MB231 cells.  
B. Ingenuity Pathways Analysis (IPA) showing the top gene networks enriched 














Figure 3.2 Inflammatory network and its related genes regulated by EZH2 
A. Inflammatory response network showing the connection to NF-κB. Red 
molecules in the network represented the genes that are downregulated upon 
EZH2 depletion in MB231 cells. 
B. Downregulation of the genes following EZH2 depletion shown in (A) was 













RelA and RelB are the two main transcription factors in the NF-κB pathway with 
transactivational activity and they serve to modulate the canonical and non-canonical NF-κB 
pathway respectively. Depletion of these transcription factors would allow the identification 
of their respective potential target genes in the context of our model cell line, MB231. Hence, 
in order to identify NF-κB target genes that are positively regulated by EZH2, we individually 
depleted RelA and RelB in MB231 cells and compared the gene expression profiles with that 
in EZH2-depleted cells. We identified 129 and 101 genes that were down-regulated following 
RelA and RelB knockdown (using 2-fold cut off), respectively. Surprisingly, we observed that 
there was a common set of 62 genes co-regulated by both RelA and RelB (Figure 3.3). This 
result was unexpected as it was previously reported that RelA and RelB govern the expression 
of distinct sets of targets that would lead to different responses upon activation. We also 
noticed that among RelA and RelB-regulated genes, 48 were concomitantly downregulated by 
EZH2 knockdown, showing that a significant set of NF-κB targets (approximately 28%) 
appeared to be down-regulated by EZH2 depletion (p<0.001). The overlap between the 
regulated genes further supports the notion EZH2 could positively modulating the expression 














Figure 3.3 Overlap of EZH2-, RelA, and RelB-regulated genesets. 
Venn diagram showing the overlapping of genes downregulated upon depletion of 
EZH2, RelA or RelB in MB231 cells. 
EZH2 knockdown 









The overlap of EZH2 and RelA/RelB regulated genes raised at least two possibilities: 
(i) EZH2 knockdown reduces RelA/RelB expression levels; (ii) EZH2 knockdown 
downregulates RelA/RelB transcriptional activity. To justify the effect of EZH2 knockdown 
on NF-κB expression or activity, we performed Western blot analysis and NF-κB-specific 
luciferase reporter assay in MB231 and another BLBC cell line, BT549. Based on the results, 
the first possibility was eliminated as EZH2 depletion affected neither RelA nor RelB protein 
expression levels (Figure 3.4A, Bottom). On the other hand, from the NF-κB reporter assay, 
EZH2 knockdown clearly reduced the reporter activity of NF-κB (Figure 3.4A, Top) in both 
MB231 and BT549 cell lines, showing that the effect was not specific and limited to a single 
cell line. As the positive controls, NF-κB reporter activities were reduced robustly upon RelA 
or RelB knockdown, indicating that the signals generated from the NF-κB reporter plasmid 
could reflect the transcriptional activity of both RelA and RelB. Noteworthy, the protein 
expression of RelB was significantly reduced after the depletion of RelA. This was not 
surprising as RelB is known to be a direct target of RelA (Bren et al., 2001). This could 
impose a problem in this project as any overlap between the effects of RelA and RelB 
depletion could be mediated through indirect effect exerted by RelA on RelB expression. 
Nevertheless, this problem could be partially addressed by performing RelA and RelB ChIP 
in the later part of this thesis.  
In concordance with reduced NF-κB reporter activity following EZH2 depletion, 
expression levels of NF-κB targets TNF and IL8 were markedly down-regulated in both 
MB231 and BT549 cells (Figure 3.4B). Increasing evidences have pointed to the importance 
of TNFα in promoting breast cancer aggressiveness (Acharyya et al., 2012; Li et al., 2012). 
Biologically, TNFα activates RelA activity by triggering the degradation of IκB and hence the 
translocation of RelA into the nucleus via the canonical pathway. As RelB is a target gene of 
RelA, TNFα treatment leads to induction of both RelA and RelB activity.  Here, we showed 
that in addition to the basal activity of NF-κB, TNFα-induced NF-κB activation was also 





findings validated a positive role of EZH2 in modulating the NF-κB-dependent transcription 
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Figure 3.4 EZH2 depletion reduced NF-κB reporter activity. 
A. NF-κB luciferase reporter activity in MB231 and BT549 cells upon 
knockdown of EZH2, RelA or RelB (Top). Knockdown efficiency was shown 
in immunoblot analysis (Bottom). 
B. qRT-PCR assay results demonstrating relative mRNA expression levels of 
NF-κB target genes, IL8 and TNF, in MB231 and BT549 cells upon EZH2 
depletion. 
C. NF-κB luciferase reporter activity in MB231 and BT549 cells upon EZH2 













































































































































3.2 EZH2 Positively Modulates NF-κB Target Gene Expression 
Independently of Histone Methyltransferase Activity.  
 
The effect of EZH2 knockdown on NF-κB transcription activity could be due to the 
off-target effects of the siRNA used. To exclude this possibility, NF-κB reporter assay was 
repeated using another siRNA that targets the 5’UTR region of EZH2 mRNA. To further 
validate the specific effect of EZH2, we performed rescue assays restoring NF-κB reporter 
activity after EZH2 silencing by overexpressing wild-type EZH2 (EZH2 WT). Rescue assay 
is only possible when the siRNA used is unable to target the exogeneously expressed EZH2, 
which the mRNA transcript lacks of 5’- and 3’-UTR regions. As anticipated, the reduced NF-
κB reporter activity resulting from the depletion of EZH2 using EZH2 5’UTR siRNA could 
be rescued by ectopic expression of wild type EZH2 in both MB231 and BT549 (Figure 3.5, 
Top). This result supports the specificity of EZH2 in regulating NF-κB activity. The 
incomplete rescue of NF-κB activity by EZH2 WT could be due to the low efficiency of 
transient overexpression as such transfection could normally take effect on only about 30% of 
cell population. Although the protein level of the ectopic EZH2 WT appeared higher than the 
untransfected control (Figure 3.5, Bottom), that could be a result of amplification of 
exogeneous gene product from the 30% of transfected cells.  
EZH2 SET domain is required to induce gene silencing by catalyzing H3K27 
trimethylation. We next asked whether such a catalytic function is required for EZH2 to 
positively regulate NF-κB-dependent transcription. We compared the abilities of EZH2 WT 
and EZH2 SET domain deletion mutant (EZH2 SETΔ) in rescuing the downregulation of NF-
κB activity in EZH2-depleted cells. In both MB231 and BT549 cells, depletion of the 
endogenous EZH2 and the associated H3K27me3 by this siRNA were effectively rescued by 
the ectopic expression of the EZH2 WT but not EZH2 SETΔ, demonstrating the functionality 
of these overexpression constructs (Figure 3.5, Bottom). Interestingly, overexpression of 





strongly restored NF-κB activity after EZH2 knockdown (Figure 3.5, Top), suggesting a SET 
domain-independent function of EZH2 on modulating NF-κB activity. Notably, ectopic EZH2 
SETΔ consistently displayed higher levels of protein accumulation compared to the ectopic 
EZH2 WT, this is in accordance with the stronger rescue of NF-κB activity by EZH2 SETΔ 


























siEZH2:      -     +    +    +        -     +    +    + 
EZH2 WT:      -     -    +    -         -     -     +     - 





Figure 3.5 EZH2 WT and SETΔ rescued NF-κB reporter activity. 
NF-κB luciferase reporter activity in MB231 and BT549 transfected with EZH2 5’-
UTR siRNA followed by over-expression of EZH2 WT or SETΔ (Top). Western blot 





To further substantiate the evidences of SET domain-independent function of EZH2 
in regulating NF-κB activity, EZH2 WT and EZH2 SETΔ were stably expressed in an 
immortalized human mammary epithelial cell line, HMEC, generated through retroviral 
infection. In consistent with the results of transient overexpression, stable overexpression of 
EZH2 SETΔ resulted in a robust induction of NF-κB reporter activity (Figure 3.6A, Top). 
However, stable overexpression of EZH2 WT had only a modest effect, probably due to 
insufficient overexpression of EZH2 (Figure 3.6A). Concomitantly, the expression of of NF-
κB targets like TNF, IL6, and IL8 was induced strongly in EZH2 SETΔ stable cell line (Figure 
3.6B). 
Notably, ectopic expression of EZH2 SETΔ depletes the protein expression of 
endogeneous EZH2 and the corresponding H3K27me3 mark through an unknown mechanism 
(Figure 3.6A, Bottom). The stronger enhancing effect of EZH2 SETΔ on NF-κB transcription 
activity could imply a scenario whereby the SET-domain independent function is enriched in 
EZH2 SETΔ-expressing cell line when compared to the EZH2 WT-expressing cell line as the 
EZH2 WT variant could be potentially recruited and engaged in PRC2-mediated activity 
rather than the SET-domain independent function. Collectively, these findings support the 
hypothesis in which EZH2-mediated activation of NF-κB signaling does not require histone 












                                      
                                                                              
Figure 3.6 Stable overexpression of EZH2 WT and SETΔ induced NF-κB 
activity. 
A. NF-κB luciferase reporter activity in HMEC cells overexpressing EZH2 WT 
or SETΔ (Top). Western blot analysis of indicated samples (Bottom).  
B. RT-PCR analysis of IL6, TNF, and IL8 in HMEC cells overexpressing EZH2 























































































































































3.3 EZH2 Forms a Ternary Complex with RelA and RelB in 
Aggressive Breast Cancer Cells  
 
Since EZH2 could modulate NF-κB activity independent of the SET domain function, 
these findings brought up a possibility that EZH2 may directly regulate NF-κB signaling. To 
explore this possibility, we began to ask whether EZH2 regulates NF-κB signaling through 
physical association with RelA or RelB, the two main transactivational members of NF-κB. 
To examine this hypothesis, we performed co-immunoprecipitation (Co-IP) in MB231 with or 
without the stimulation of TNFα. In each respective immunoprecipitates of RelA, RelB, or 
EZH2, we were able to detect the other two proteins, which were further enriched upon 
TNFα-treatment (Figure 3.7A). Notably, RelA was found to be co-immunoprecipitated with 
RelB, consistent with a previous report (Jacque et al., 2005). These results indicate that 
endogenous EZH2 forms a complex with RelB and RelA in MB231 cells. Yet, while SUZ12, 
a component of PRC2 (mainly contains EZH2, SUZ12 and EED), was found in EZH2 
immunoprecipitates, it was not detected in RelB or RelA immunoprecipitates. This proposed 
the ability of EZH2 to form two separate protein complexes in MB231 cells: (i) PRC2; (ii) 
EZH2/RelB/RelA.  Densitometry analysis of Western blot showed that approximately 1-2% 
of total EZH2 was associated with RelA/RelB and 4-5% of RelA/RelB interacted with EZH2 




































Figure 3.7 EZH2 physically interacted with RelA and RelB endogeneously. 
Co-IP assay using nuclear extract of MB231 cells stimulated with TNFα for 2 hours 
(Top). The bands were technically quantified three times by densitometry (Bottom).  
IgG RelA RelB EZH2 Input IP: 
TNFα:   -   +    -   +        -    +   -   +         -   +   -   +        -    + 
EZH2 RelB RelA SuZ12 








Given that EZH2 SETΔ could rescue the transcriptional activity of NF-κB, we 
hypothesized that the association of EZH2 with RelA/RelB is independent of the SET domain. 
To test this hypothesis, we overexpressed myc-tagged EZH2 WT or EZH2 SETΔ in the 
presence of RelA and RelB overexpression in HEK293T cells. HEK293T cells are 
immortalized human embryonic kidney cells, which stably expresses SV40 Large T-antigen 
that enables episomal replication and subsequent amplification of transfected plasmids 
consisting of SV40 replication origin. As a result of plasmid amplification, genes that are 
cloned into the plasmids would be transcribed at a high efficiency. Hence, HEK293T was 
chosen for transient overexpression of genes of interest. In this experiment, we adopted 
HEK293T for transient simultaneous overexpression of EZH2, RelA and RelB in order to 
study the potential physical interactions between these players. We perform individual 
immunoprecipitation of EZH2, RelA, and RelB using their respective specific antibodies and 
we observed that RelB was detected in both EZH2 WT and EZH2 SETΔ immunoprecipitates, 
which the interactions were more evident upon TNFα stimulation (Figure 3.8). Compared to 
RelB, RelA appeared to be less interactive with EZH2 and their interaction was only evident 
in EZH2 SETΔ immunoprecipitates, suggesting that EZH2 may preferentially associate with 
RelB in this experimental condition. Notably, RelA also interacted with RelB in a TNFα 
stimulation dependent manner. Interestingly, the interaction seemed to be stronger in the 
presence of EZH2 WT or EZH2 SETΔ. Such differences were more evident in RelA 
precipitates. This infers that the presence of EZH2 WT or EZH2 SETΔ may enhance the 




















Figure 3.8 EZH2 WT and  SETΔ physically interacted with RelA and RelB. 
Co-IP assay using nuclear extract of 293T cells over-expressed with RelA, RelB, and 
myc-tagged EZH2 constucts followed by TNFα stimulation for 2 hours. 
TNFα:  -   +  -  +   -  +   -  +  -  +  -   +     -  +  -  +   -  +  -  +  -   +  -  +      -  +   -  +   -  + 







































































































To demonstrate a direct interaction between EZH2 and RelA/RelB, we performed an 
in vitro pull down assay using bacterial expressed recombinant proteins. As shown in Figure 
3.9A, both MBP-tagged RelA or RelB recombinant fusion proteins could associate with GST-
tagged EZH2. MBP protein served as a negative control in the pull down. This indicated that 
EZH2 could directly interact with RelA and RelB and such interaction did not require the 
presence of other components in mammalian systems. Nevertheless, this pull down 
experiment could suggest two different scenarios: (i) EZH2 interacts with both RelA and 
RelB in the same complex, and; (ii) EZH2 interacts with RelA and RelB in two separate 
complexes. To examine the first scenario, we designed a re-IP assay. We first performed in 
vitro pull down of the GST-tagged EZH2 followed by the elution of the pull down complexes 
using reduced glutathione. The eluates were then subjected to a sequential co-
immunoprecipitation of the second component (i.e. RelA) and attempt to detect the third 
component (i.e. RelB) in the complex. If EZH2 interacts with RelA and RelB to form 
independent complexes, the third component would not be enriched during the second 
immunoprecipitation assay. To facilitate the formation of ternary complex, the MBP tags of 
RelA and RelB were removed by TEV protease treatment in order to reduce steric hindrance. 
Consistent with the observation in Figure 3.9A, both RelA and RelB were enriched in the pull 
down of GST-EZH2 but not the negative control, GST (Figure 3.9B). When we further 
subjected the eluates of GST pull down to RelA-specific immunoprecipitation, RelB was only 
detected in GST-EZH2 pull down sample, but not in either the IgG counterpart or GST 
control pull down (Figure 3.9B). This suggests that the EZH2-interacting RelA could 














Figure 3.9 EZH2, RelA, and RelB direct interacted with each other to form a 
ternary complex.  
A. In vitro pull down assay using recombinant MBP-RelA and MBP-RelB as 
well as GST and GST-EZH2 proteins.  
B. In vitro re-immunoprecipitation assay using recombinant RelA and RelB as 
well as GST and GST-EZH2 proteins. GST or GST-EZH2 and its interacting 
partners were affinity purified as described in experimental procedures and 
further immunoprecipitated using RelA-specific or control IgG and subjected 
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To demonstrate the presence of the ternary complex endogeneously in cells, re-IP is 
not plausible as competitive peptides are not available for elution of the complex from the 
first pull down process. Alternative elution approaches such as detergent-containing buffer 
and high temperature were also not feasible as these conditions would probably disrupt the 
ternary complex. Thus, to investigate the presence of endogeneous ternary complexes, we 
performed a knockdown IP experiment to assess the effect of the depletion of one component 
on the interaction between the other two components. As a result, the depletion of 
endogenous RelB greatly reduced the interaction between endogenous EZH2 and RelA in 
MB231 cells, suggesting that the presence of RelB is important for EZH2-RelA complex 
formation (Figure 3.10). One possible explanation could be RelB is stabilizing EZH2-RelA 
interaction by direct association with the complex. Taken all together, these biochemical data 
indicate the formation of a ternary complex between endogenous EZH2, RelB and RelA in 
MB231 cells and provide a potential mechanistic link to the positive regulation of NF-κB 








































Figure 3.10 RelB depletion disrupted EZH2-RelA interaction. 





3.4 EZH2 and RelA/RelB Co-Regulate a Subset of NF-κB Targets by 
Inter-Dependent Promoter Occupancy 
 
Given that EZH2 may regulate NF-κB target genes through forming a complex with 
RelA and RelB, which both have known oncogenic roles in aggressive breast cancers (Helbig 
et al., 2003; Wang et al., 2007), we next sought to identify EZH2/RelA/RelB-co-regulated 
NF-κB targets that might be associated with aggressive phenotype of BLBC. Using non-
supervised hierarchical clustering of genes identified through gene expression profiling of 
MB231 cells that were depleted of EZH2, RelA or RelB (2-fold cut-off) with or without 
TNFα stimulation, two distinct clusters of genes were revealed: (i) one cluster of genes (n=46) 
appeared to be regulated by all three components of EZH2, RelA, and RelB and showed a 
strict dependency on EZH2, RelA, and RelB upon TNFα treatment while (ii) another cluster 
of genes (n=6) seemed to be regulated mainly by RelA and was capable to be induced by 
TNFα when RelB or EZH2 was depleted, but remained downregulated when RelA was 
depleted (Figure 3.11A). Notably, most of the genes from the second cluster geneset were 
downregulated at the basal level upon EZH2 and RelB depletion, possibly due to the 
reduction of many cytokines such as TNFα and IL6 that could otherwise drive autocrine 
responses of NF-κB signaling. Short-term TNFα treatment was shown to activate RelA more 
rapidly and more robustly without much influence on RelB activity (Derudder et al., 2003). 
This allows the distinction of RelA and RelB target genes. Hence, we speculated that when 
TNFα was added exogeneously, endogeneous RelA could be stimulated and the expression of 
the target genes that were mainly regulated by RelA could be restored even if EZH2 or RelB 
was depleted. This trend of regulation was further validated by RT-PCR analysis of 
representative genes from each cluster (Figure 3.11B).  

















Figure 3.11 Two clusters of EZH2/NF-κB regulated genes. 
A. Non-supervised hierarchical clustering of NF-κB target genes that were co-
regulated with EZH2. Gene sets were obtained from microarray gene 
expression profiling of MB231 cells depleted of EZH2, RelA, and RelB 
followed by TNFα treatment for 4 hours.  
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Regulated by EZH2, RelB , and RelA 






The dependence of IL6 or TNF expression on RelB was further verified by stable 
overexpression of RelB in MB231 cells. RT-PCR analysis showed that IL6 or TNF expression 
was robustly elevated upon ectopic expression of RelB, whereas the expression levels of these 
genes was less responsive to ectopic RelA overexpression (Figure 3.12). Noticeably, EZH2 
remained essential in regulating IL6 and TNF expression despite of the overexpression of 
RelB or RelA. In contrast, IL8 and BIRC3 from the second cluster geneset were neither 
responsive to ectopic RelB, nor altered after EZH2 knockdown upon TNFα treatment (Figure 
3.12). In concordance with the hypothesis that the second cluster geneset was mainly 
regulated by RelA, exogeneous expression of RelA was sufficient to induce the expression of 
IL8 and BIRC3 to at least by two-fold. This elevation of expression was less obvious under 
TNFα stimulation possibly because RelA overexpression was adequate to turn on the 
expression of its target genes. Taken together, these findings support that EZH2-regulated 
NF-κB targets such as IL6 and TNF from the first cluster are EZH2-, RelA- and RelB-
dependent, while the second cluster of NF-κB target genes such as IL8 and BIRC3 are not 




































































































Figure 3.12 Ectopic expression of RelA and RelB induced the expression of 
different subsets of genes. 
RT-PCR analysis of representative genes in MB231 cells overexpressing RelA or 
RelB followed by depletion of EZH2 with or without TNFα treatment for 4 hours. 
TNFα:   -    +   -    +       -    +    -   +        -    +    -   +  












To understand the mechanisms by which EZH2 selectively cooperates with RelA and 
RelB towards NF-κB target gene regulation, we next analyzed the promoter binding of EZH2, 
RelB, and RelA by performing chromatin immunoprecipitation (ChIP) in TNFα-treated 
MB231. Binding signals were then detected using a panel of PCR primer pairs that spanned 
the gene promoters of IL6, TNF, IL8 and BIRC3. Significantly, all three proteins were found 
to be highly enriched in both IL6 and TNF promoters with binding peaks around the 1000-
500bp upstream of the transcription start sites (Figure 3.14). However, despite a high EZH2 
enrichment, no corresponding H3K27me3 enrichment was detected on IL6 and TNF promoter, 
further supporting a histone methylation-independent activity of EZH2. In contrast, IL8 and 
BIRC3 promoters only displayed high RelA binding, but not EZH2 and RelB binding. These 







Cluster 1 - Regulated 
by RelB, EZH2 and 
RelA
Cluster 2 - Mainly 
regulated by RelA RelA
Figure 3.13 A Model proposed two modes of transcription regulation by EZH2 
and NF-κB. 
A model proposed the two modes of transcription regulation of the target genes by 








































































Figure 3.14 Promoter occupancy of EZH2, RelA, and RelB in MB231. 
ChIP assay of EZH2, RelA, RelB, and H3K27me3 on the promoters of TNF, IL6, IL8, 
and BIRC3 in MB231 cells treated with TNFα for 2 hours. Primer pairs encompass a 
2.5 kb surrounding the TSS (transcription start site) for TNF, IL8, and BIRC3 with 
approximately 500 bp interval. P3 is located in the region within 500bp upstream of 
TSS. P4 is located the region within 500bp upstream of TSS for IL6. The percent 
input of H3K27me3 ChIP was plotted on the right y-axis. Quantification of binding 
was determined as a percent of input DNAs. 





Recall in Figure 3.10, depletion of RelB affected the complex formed between RelA 
and EZH2. If first cluster geneset was dependent of the ternary complex of EZH2/RelA/RelB, 
disruption of the complex by depleting any of the three components could affect the DNA 
binding of the other two. To investigate this likelihood, knockdown ChIP assay was 
performed. Indeed, TNFα-induced recruitments of RelA and RelB to IL6 and TNF promoters 
were markedly reduced by EZH2 knockdown (Figure 3.15). Similarly, knockdown of RelB 
decreased the recruitment of EZH2 and RelA. Importantly, the recruitment of RelA on the 
promoters of IL8 and BIRC3, which were void of EZH2 and RelB binding, was not influenced 
by EZH2 or RelB knockdown, indicating that the reduction of RelA recruitment to promoters 
of IL6 and TNF after EZH2 or RelB knockdown was not a general effect to all RelA target 
genes. These results indicate that the recruitment of EZH2, RelA, and RelB to IL6 and TNF 
gene promoters are inter-dependent. In contrast, EZH2 or RelB knockdown had no effect on 
RelA binding to IL8 and BIRC3 promoters. These results further support that the genes from 
cluster two (Figure 3.11B) were mainly regulated by RelA and were not directly regulated by 
EZH2 and RelB.  
Albeit knockdown ChIP has demonstrated the interdependency of EZH2, RelA, and 
RelB occupancy at IL6 and TNF promoter, there is still insufficient evidence to show co-
occupancy of all three factors at the promoter. Thus, extensive pair-wise sequential ChIP was 
carried out. Following the EZH2 first ChIP, both RelA and RelB binding was enriched in 
EZH2-bound IL6 and TNF promoters, but not in IL8 and BIRC3 promoters (Figure 3.16), 
indicating that RelA/RelB were concurrently bound to these promoter with EZH2. 
Comparable results were also obtained in RelA or RelB first ChIP experiments. Nevertheless, 
pairwise sequential ChIP could only showed the co-occupancy of two factors. Binding of the 
ternary complex could hardly be demonstrated as triple sequential ChIP was technically 
unfeasible. Taken together, we conclude that EZH2, through interacting with RelA and RelB, 
is required for the activation of a subset of NF-κB target genes in BLBC cells. This 







































































































EZH2 RelA ChIP: 
Figure 3.15 Knockdown-ChIP of EZH2, RelA, and RelB in MB231. 
ChIP assay of EZH2, RelA or RelB on the promoter of TNF, IL6, IL8, and BIRC3 
genes in MB231 cells depleted with EZH2 or RelB, followed by TNFα treatment for 2 
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IL6 TNF IL8 BIRC3 
IL6 TNF IL8 BIRC3 
IL6 TNF IL8 BIRC3 
Figure 3.16 Sequential ChIP of EZH2, RelA, and RelB in MB231. 
Sequential ChIP assay was performed to assess in vivo co-occupancy of EZH2, RelA, 
and RelB on the chromatin. First ChIP and second ChIP antibodies were indicated as 
the chart title and x-axis labels. Quantification of binding was represented as fold 





3.5 NF-κB Target Gene Signature Co-Regulated by EZH2, RelA, and 
RelB Discriminates Basal vs Luminal Subtype of Breast Cancers and 
is Associated with Poor Disease Outcome 
 
RelB was reported to be aberrantly expressed in BLBC. In this study, we 
demonstrated the importance of RelB for EZH2-RelA interaction in the BLBC cell line, 
MB231. Hence, the overexpression of RelB could be the cause that allows the formation of 
EZH2/RelA/RelB complex, leading to the subsequent increased expression of target genes 
regulated by this complex. To determine whether EZH2/RelA/RelB co-regulated NF-κB 
target geneset (n=46) identified in MB231 cells are also associated with other BLBC cell lines, 
we interrogated the published gene expression dataset generated from 54 breast cancer cell 
lines, including 26 basal and 25 luminal (and 3 uncharacterized) (Neve et al., 2006) and 
performed non-supervised clustering analysis based on this geneset. The expression of ER 
and its essential cofactors, FOXA1 and GATA3 were shown to validate the luminal or BLBC 
status of the cell lines. Strikingly, EZH2 and NF-κB-coregulated gene list was able to 
efficiently separate basal from luminal type breast cancer cells with approximately 90% 
proper segregation (Figure 3.17).  
 Although the 46 genes were demonstrated to be coregulated by EZH2/RelA/RelB in 
MB231, it was understandable that not all of these genes would remain coregulated in other 
BLBC cell lines due to different cellular context. Based on the clustering of EZH2/RelA/RelB 
coregulated genes, we identified a cluster of 12 genes that were consistently expressed higher 
in BLBC compared to the luminal breast cancer cell lines at both individual gene and average 
gene expression levels (p=0.0001) (Figure 3.17 and 3.18A). This indicates that deregulation 
of these genes is not just limited to MB231 cells, but common to BLBC cell lines in general. 
Notably, gene set comprising of these 12 genes include IL6, SAA1, and PTGS2 (encoding 
Cox2) that have been previously shown to be associated with aggressive breast cancers and 





To further establish the clinical significance of this finding, we carried out an 
expression analysis of these 12 genes using two additional microarray datasets from Farmer 
and Netherlands breast cancer cohorts (Bos et al., 2009; Farmer et al., 2005) that were 
downloaded from Oncomine. Consistent with the analysis in the cell line dataset, the averaged 
expression of the 12 signature genes were significantly higher in basal or ER negative breast 
cancer samples as compared to luminal or ER positive breast tumors in these two cohorts of 
tissue samples (Figure 3.18B and 3.18C). The expression of the 12 signature genes was 
inversely correlated with the expression of ER, FOXA1 and GATA3, markers of luminal breast 
cancer. 
Interestingly, the expression of RelB but not RelA was consistently higher in BLBC 
or ER-negative breast cancer cells in all the three datasets analyzed (Figure 3.19), in 
concordance with the higher expression of the 12 signature genes. Furthermore, based on the 
three datasets, only EZH2 showed consistent overexpression in ER-negative breast cancer or 
BLBC but not the other two core components of PRC2. These support our model that instead 
of PRC2 complex, SET domain independent function of EZH2 might be primarily responsible 













Figure 3.17 Hierarchical clustering of breast cancer cell lines based on expression 
of EZH2/NF-κB coregulated genes. 
Non-supervised clustering of 54 breast cancer cell lines based on 46 genes that were 
co-regulated by EZH2, RelB, and RelA. A subset of 12 genes showing higher 
expression in basal- vs luminal- breast cancer cell lines in the heatmap. Expressions of 
ER associated genes (ESR1, FOXA1 and GATA3), PRC2 components (EZH2, EED, 

































Figure 3.18 Expression of 12 signature genes and ER associated genes. 
Box plots showing the average expression level of the 12 signature genes and ER 
associated genes  in basal and luminal breast cancer cell lines (A); patient tissue in 
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Figure 3.19 Expression of RelA, RelB, EZH2 and other two PRC2 components. 
Box plots showing the expression level of PRC core components (EZH2, SUZ12, and 
EED) as well as RelA and RelB in basal and luminal breast cancer cell lines (A); 
patient tissue in Farmer cohort (B); and patient tissue in Netherlands cohort (C). Note: 





More importantly, Kaplan-Meier survival analysis also demonstrated a prognostic 
value of the 12 signature genes in breast cancer patients of Netherlands cohort. Specifically, 
when we classified the patients based on the mean value of the average expression levels of 
the 12 genes, the breast cancer patients with higher expression of this geneset showed lower 
brain- and lung- metastasis-free survival probabilities in Kaplan-Meier plots with P=0.0188 
and P=0.0152, respectively (Figure 3.20A). When we further stratified the patients based on 
quartile expression of the 12 genes, more significant differences in brain- and lung- 
metastasis-free survival probabilities were observed with P=0.0025 and P=0.0065, 
respectively (Figure 3.20B). This indicates that the clinical outcome correlates well with the 
expression levels of the 12 signature genes. Intriguingly, no difference was observed in bone 
metastasis-free in these patients regardless of the method of stratification either based on 
mean or quartile expression. This result was coincidental with the clinical observation that the 
preferred sites of distal metastasis in BLBC patients are brain and lung, but not bone. As a 
control, NF-κB targets that are not regulated by EZH2 or RelB were not found to be 
associated with brain or lung metastasis-free survival (Figure 3.21). Taken together, these 
results indicate that the expression levels of the 12 genes inversely correlated with the brain- 
and lung- metastasis-free survival probabilities of breast cancer patients. This highlights the 
clinical relevance of EZH2/RelA/RelB-dependent gene transcription in promoting the 
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Brain metastasis-free survival Lung metastasis-free survival
Figure 3.20 Kaplan-Meier analyses based on expression of 12 signature genes. 
A. Kaplan-Meier analyses of disease-specific survival of breast cancer patients of 
Netherlands cohort. Patients were stratified by average expression of the 12 
signature genes defined based on mean values. 
B. Kaplan-Meier analyses of (A) by stratifying patients with quartiles partition.  
C. Kaplan-Meier analyses of bone metastasis-free survival in breast cancer 
patients of Netherlands cohort whom were stratified by average expression of 
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Figure 3.21 Kaplan-Meier analyses based on expression of EZH2/RelB 
independent RelA regulated genes 
Kaplan-Meier analyses of disease-specific survival of breast cancer patients of 
Netherlands cohort. Patients were stratified by average expression of the EZH2/RelB-
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To validate the role of EZH2, RelA, and RelB in regulating the invasiveness of breast 
cancer cells, we performed transwell invasion assay using MB231 transient knocked-down 
with EZH2/RelA/RelB individual gene or in combination. We showed that each of the EZH2, 
RelA or RelB depletion reduced the invasive capacity of MB231 cells, and a combined 
knockdown gave rise to a more profound inhibition (Figure 3.22A). A similar result was also 
observed when we performed 3D matrigel assay (Figure 3.22B). 3D matrigel assay assesses 
the capability of cancer cells in conferring anchorage-independent growth, a characteristic of 
aggressive breast cancer. Overall, these results indicate that EZH2, RelA, and RelB can 
regulate the invasive and aggressive behaviors of BLBC cells through both overlapping and 































































siNC siEZH2 siRelA siRelB
siEZH2+siRelA
+siRelB
Figure 3.22 EZH2, RelA, and RelB depletion reduced invasiveness and 
aggressiveness of MB231. 
A. Transwell invasion assay was performed on EZH2, RelA, and/or RelB 
depleted MB231.  
B. 3D matrigel assay was performed on EZH2, RelA, and/or RelB depleted 
MB231. Phase-contrast images were taken under 40X magnification on the 



























4.1 EZH2 Negatively Regulates NF-κB Target Genes in ER Positive 
Luminal Breast Cancer Cells 
 
Our lab has previously reported that EZH2 depletion in ER positive luminal MCF7 
cells activates the expression of many inflammatory cytokines, including known NF-κB 
targets (Sun et al., 2009). This discrepancy between luminal and basal-like breast cancer cell 
lines such as MB231 and BT549 suggests that EZH2 could acts differently in regulating NF-
κB target gene expression, depending on the cellular context. ER has been known for long to 
repress NF-κB activity and target gene expression (Nakshatri et al., 1997; Pratt et al., 2003). 
In addition, ER has also been reported to repress RelB expression (Wang et al., 2007) in 
MCF7 cells. Given that RelB plays essential roles in the formation and DNA binding activity 
of EZH2/RelA/RelB complex (refer to Chapter 3), the underexpression of RelB in luminal 
cells could lead to an altered function of EZH2 in regulating NF-κB targets. In agreement 
with the earlier findings, we found many NF-κB targets were highly expressed in ER negative 
MB231 cells but repressed in ER positive MCF7 cells. This pattern of expression was 
inversely correlated with the expression of ER and the two well-known ER co-factors FOXA1 










Figure 4.1 Inversely correlated expressions of NF-κB targets and ER-related 
genes in MB231 and MCF7. 
Bar graphs showing the mRNA levels of NF-κB target genes (Left) and ER-associated 
genes (Right) in MB231 and MCF7. Raw values were extracted from a microarray 








































































































Consistent with the previous study (Sun et al., 2009), the depletion of either EZH2 or 
ER in the ER-positive MCF7 and T47D breast cancer cells resulted in marked induction of 
IL6 and IL8 expression at both the basal level and after TNFα treatment (Figure 4.2, Top), 
validating the repressive roles of EZH2 and ER in regulating NF-κB target genes. To confirm 
that IL6 and IL8 were NF-κB targets in these two cell lines, knockdown of RelA was 
performed and as expected, their expressions were markedly abolished. It is worth to note that 
the depletion of EZH2 or ER did not affect RelA protein level (Figure 4.2, Bottom), 















Figure 4.2 ER and EZH2 depletion enhanced IL6 and IL8 expressions. 
qRT-PCR analysis of IL6 and IL8 expression in MCF7 (Left) and T47D (Right) upon 
ER, RelA, or EZH2 knockdown followed by TNFα treatment for 4 hours. Relative 

















































































































































4.2 EZH2 interacts with ER and co-occupy NF-κB target genes 
promoter together with the enrichment of H3K27me3 mark 
 
EZH2 has been previously shown to function as a corepressor in ER-mediated gene 
regulation in ER-positive breast cancer cells (Hwang et al., 2008). In attempt to explore this 
potential role of EZH2 in MCF7 cells, we first conducted co-IP assay to detect the interaction 
between the PRC2 components, EZH2 and SuZ12, with ER in MCF7 cells. Indeed, both 
EZH2 and SuZ12 were detected in ER immunoprecipitates, and similarly, ER was detected in 
EZH2 immunoprecipitates (Figure 4.3). Importantly, in both immunoprecipitates, RelA and 
RelB were not detected. This indicates that PRC2 formed a complex with ER but not with 
RelA/RelB in MCF7 cells.  Intriguingly, the PRC2-ER interaction was disrupted after TNFα-
treatment. This suggests a possibility that ER may recruit PRC2 to promoters of NF-κB target 
genes for transcriptional repression but upon TNFα treatment, the repressive PRC2-ER 
complex might be disrupted and shattered, potentially due to the recruitment of NF-κB and its 














TNFα:     - +       - +      - +       - +
IgG ERα EZH2 Input
MCF7
SuZ12
Figure 4.3 ER interacted with EZH2 and SuZ12 and dissociated in response to 
TNFα. 






To examine this speculation, we performed ChIP analysis in MCF7 cells. We 
detected marked enrichment of EZH2 and ER on IL6 and IL8 promoters, with concomitant 
high level of H3K27me3 but low level of RelA binding under unstimulated condition (Figure 
4.4A). This observation is consistent with the reduced expression of IL6 and IL8, which could 
be reversed by ER or EZH2 depletion in MCF7 cells (Figure 4.2). Moreover, following TNFα 
treatment over time, the amount of EZH2 and ER as well as H3K27me3 associated with IL6 
and IL8 promoters dropped steadily, in contrast to the increased recruitment of RelA (Figure 
4.4B). This change of promoter occupancies by these factors corresponded well to the strong 
induction of IL6 and IL8 (Figure 4.2). These observations support that ER co-recruitment of 
PRC2 to NF-κB target genes may account for their silenced expression in MCF7 cells under 
unstimulated condition. Under unstimulated condition, ER could recruit PRC2 complex to IL6 
and IL8 promoter to catalyze H3K27 trimethylation, leading to subsequent suppression of the 
target genes. Under TNFα-stimulated condition, the recruitment of RelA transactivational 
complex, the concomitant reduction of PRC2 complex would cause a decrease in H3K27me3, 
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P1 P2 P3 P4 P5P1 P2 P3 P4 P5
IL6
Figure 4.4 ER, EZH2, and H3K27me3 enrichment on IL6 and IL8 promoter 
reduced upon TNFα stimulation. 
A. ChIP assay of EZH2, H3K27me3, ER, or RelA on the promoters of IL6 and 
IL8 in unstimulated MCF7 cells. Primer pairs spanning a 2.5 kb genomic 
region surrounding the TSS are indicated. P3 is located in the region within 
500 bp upstream of TSS. Quantification of enrichment was determined as a 
percent of input DNAs.  
B. ChIP assay of EZH2, H3K27me3, ER, or RelA on the promoters of IL6 (P3) 
and IL8 (P3) in MCF7 cells treated with TNFα for indicated times. 







4.3 Ectopic RelB expression alters EZH2 regulation of NF-κB targets 
 
One potential reason underlying the difference of EZH2 functions in modulating NF-
κB target gene expression in BLBC and luminal breast cancer cells could be the 
underexpression of RelB. To investigate whether the restoration of RelB expression in 
luminal breast cancer cells could alter EZH2 function, we stably overexpressed RelB in 
MCF7. Excitingly, ectopic RelB overexpression in MCF7 cells results in strong induction of 
IL6, which could be reversed by EZH2 knockdown (Figure 4.5). In contrast, RelB 
overexpression in MCF7 cells only resulted in a modest induction of IL8 and EZH2 
knockdown caused further elevated its expression. These results partially recapitulated the 
phenomena observed in the BLBC cell line, MB231, in two ways: (i) RelB governed the 
expression of IL6 but not IL8; and (ii) EZH2 could positively regulate IL6 expression in the 
presence of RelB. Although IL8 appeared to remain negatively regulated by EZH2 upon RelB 
overexpression, this could be reasoned by the existence of PRC2-dependent ER-mediated 
repression of the gene, which is independent of RelB. Taken together, these results highlight a 






























































Figure 4.5 Ectopic RelB expression in MCF7 reversed EZH2 regulation of IL6 
expression. 
RT-PCR analysis of IL6 and IL8 mRNAs in MCF7 cells with stable overexpression of 




































Based on the collective results of Chapter 3 and Chapter 4, we proposed a model for 
EZH2 regulation of NF-κB target gene expression in ER positive and ER negative breast 
cancer cells that is summarized in Figure 5.1.  In ER negative breast cancer, overexpression 
of both EZH2 and RelB forms a complex with RelA to confer constitutive activation of NF-
κB target gene expression. On the other hand, in ER positive breast cancer cells where RelB 
expression is repressed, ER recruits PRC2 to NF-κB target gene promoters and function as a 
canonical epigenetic repressor. The differential expression of ER and RelB in the two 
contexts may be crucial for switching the role for EZH2 in regulating NF-κB target gene 
expression. Based on this model, we highlighted that EZH2 could play opposing roles in 
regulating NF-κB network through distinct mechanisms in a cellular context-specific 










Repression of NF-κB by ER-EZH2 
complex





Cytokines released results in positive 
feedback loop 
Constitutive activation of NF-κB 
IL6, IL8
Figure 5.1 A proposed model of context-dependent EZH2 modulation of NF-κB 
pathway in breast cancer. 
In ER-negative basal-like breast cancer cells, EZH2 acts as a co-activator of RelA and 
RelB to promote the expression of NF-κB target genes such as TNF and IL6, which in 
turn activates NF-κB signaling through a positive feedback, leading to constitutive 
activation of NF-κB target gene expression. In ER-positive breast cancer cells, ER 
recruits PRC2 complex to the promoter of NF-κB target genes, leading to epigenetic 

























6.1 New mode of NF-κB Constitutive activation in Aggressive Breast 
Cancers 
 
As described in Section 1.3.2.2, several mechanisms have been proposed to account 
for the constitutive activation of NF-κB signaling in cancers, particularly in leukemia. For 
instance, Rel was found to be amplified in B-cell lymphoma, which led to hyperactivation of 
target genes in canonical NF-κB pathway. Besides, shorten IκB half-life and IκB mutation 
were observed in B-cell lymphoma and Hodgkin lymphoma, respectively, which released 
RelA from inhibition, leading to constitutive activation of canonical NF-κB pathway.  
However, in breast cancer, mutations or genomic amplication of the components in 
the NF-κB pathway are uncommon. In search for the potential mechanisms conferring 
constitutive NF-κB activation, two independent studies led by Struhl K (Iliopoulos et al., 
2009) and Luo JL (Rokavec et al., 2012) reported a similar conclusion: IL6 expression 
induced by a transient oncogenic “kick” was sufficient to drive the feed forward response of 
NF-κB pathway, leading to its constitutive activation (Figure 6.1). Specifically, both of these 
studies adopted MCF10A, an immortalized mammary epithelial cell line, as the model system 
and triggered the cells with transient SRC activation or MCP1 derived from monocyte 
conditioned medium. Consequently, induction of IL6 and concomitant suppression of 
microRNA, Let-7 or miR200c, would maintain the positive feedforward loop of NF-κB 
pathway activity. The self-sustainability of this loop was evident by the continuation of the 

















However, the findings of these two studies could not fully explain why constitutive 
activation of NF-κB is observed more profoundly in ER-negative BLBC compared to ER-
positive luminal breast cancer. If transient activation of SRC or MCP1 is adequate to allow 
constitutive activation of NF-κB pathway, the chances of getting constitutively activated 
should be similar in BLBC and luminal breast cancer as the SRC and MEK pathways were 
activated in both cancer subtypes (Acosta et al., 2003; Rakha et al., 2008). Thus, one can 
speculate that additional pre-existing factors are required to be present in BLBC for sustaining 
the positive feedforward loop.  
Based on our study, we put forward a model that supports this notion. That is, the 
overexpression of RelB with a concurrent absence of ER in BLBC might predispose 
activation of NF-κB by EZH2. Low expression of ER could be the cause of an enhanced 
expression of RelB in BLBC. Consequently, high level of RelB enhances the DNA binding of 
RelA and facilitates transactivation of NF-κB target genes together with EZH2. By regulating 
NF-κB pathway at the transcription factor level, constitutive activation of NF-κB could be 
achieved by circumventing the negative feedback mechanisms of the pathway such as the 
elevation of IκB production. 
  
Figure 6.1 Two proposed models of constitutive activation of NF-κB in breast 
cancer. 
A. Model proposed by Struhl K. 






6.2 RelA and RelB Conundrums 
 
Mechanistically, we show that EZH2 promotes NF-κB binding to a set of target gene 
promoters possibly through direct physical interaction with RelA and RelB in BLBC cells. In 
particular, RelB is shown to play a crucial role in this regulation. Although non-canonical NF-
κB pathway mediated by RelB has been generally considered to be different from RelA-
mediated canonical pathway and governs distinct categories of target gene expression in non-
malignant models (Bonizzi et al., 2004), it was reported that RelB could recognize a more 
diversed range of κB sequences including those DNA motif bound by RelA (Fusco et al., 
2009). In this study, we clearly see a significant set of NF-κB targets genes co-regulated by 
both RelA and RelB in BLBC cells, many of which were known to be regulated by RelA 
including IL6, TNF, SAA1, and PTGS2. This indicates an oncogenic role of RelB in co-
regulating RelA targets in some malignancies and is consistent with a recent report that 
inhibition of RelB in prostate cancer could attenuate the canonical NF-κB target gene 
expression, resulting in decreased tumorigenicity (Xu et al., 2009).  
RelA:RelB interaction was first demonstrated by Marienfeld et al. using whole cell 
extracts of several T- and B-cell lines (Marienfeld et al., 2003). In their study, they found that 
the dimerization of RelA and RelB resulted in the reduction of RelA DNA binding affinity, 
demonstrated by Electrophoretic Mobility Shift Assay (EMSA) using DNA probe with a 
single κB sequence. However, this assay was limited by its inability to determine the binding 
affinity of RelA:RelB complex to other variants of κB motifs. Possibly, while the binding 
affinity of RelA was decreased in that specific κB sequence adopted in the EMSA experiment, 
the affinity could be induced in other potential binding sites in the genome. As RelB was 
reported to have a more diverse recognition of κB sequences, it is likely that by binding to 
RelB, RelA could obtain a higher affinity to these alternative sites to trigger gene 





the promoter of TNF and IL6 drop drastically, indicating an enhancing role of RelB on RelA 
DNA binding at these regions. Conversely, depletion of RelB had minimal impact on RelA 
binding on IL8 and BIRC3 promoters, suggesting that RelB only affect RelA DNA binding at 
certain regions in the genome. It would be interesting to determine whether the cis regulatory 
elements of the subset of genes co-regulated by RelA and RelB has distinct DNA motif 
sequences compared to the subset of genes regulated mainly by RelA. To achieve this, 
genome-wide ChIP sequencing assay of RelA and RelB binding in BLBC cells would be 
necessary. It is worth mentioning that the co-regulated genesets found in this study might be 
specific to BLBC cells, in which RelB is aberrantly expressed and both RelA and RelB have 







6.3 Antagonism between EZH2/ER and NF-κB pathway 
 
Intriguingly, EZH2 functions oppositely in ER positive breast cancer cells. We have 
previously shown that EZH2 could negatively regulate inflammatory gene network in ER 
positive and non-invasive breast cancer MCF7 cells (Sun et al., 2009). This discrepancy may 
arise from the heterogeneous molecular profiles embedded in the two different subtypes of 
breast cancers, in particular in relation to the ER status. It is well established that ER is 
inhibitory to both RelB and NF-κB signaling in breast cancers and that NF-κB targets are 
significantly elevated in ER negative breast tumors (Freund et al., 2003; Gamba et al.; Gionet 
et al., 2009; Kalaitzidis and Gilmore, 2005). However, the mechanism underlying this 
inhibition might not be necessary through inhibiting NF-κB DNA binding capacity (Liu et al., 
2005; Ray et al., 1997). Consistent with this notion, we show in this study that ER recruits 
PRC2 to enforce a repressive chromatin modification at NF-κB target genes, thus providing 
an alternative mechanism to silence NF-κB target gene expression.  
Based on our findings, ER-EZH2 occupancy at NF-κB target gene promoters is 
mutually exclusive with the occupancy of RelA. Upon TNFα stimulation, ER-PRC2 repressor 
complex as well as H3K27me3 mark was reduced concomitantly with an increased in RelA 
association with NF-κB targets. TNFα treatment is known to increase RelA association with 
histone acetylase CBP/p300 at its target promoters (Gerritsen et al., 1997; Perkins et al., 
1997). We postulate that the increased histone acetylation may confer a more open chromatin 
architecture that is not favourable for PRC2 recruitment upon TNFα treatment. Besides, 
TNFα stimulation of RelA led to the decrease of H3K27me3 mark as early as 15 minutes, 
suggesting that certain machinery could be turned on rapidly to actively remove the repressive 
mark. Interestingly, it was reported that induction of NF-κB pathway could upregulate the 
expression of Jumonji D3 (JMJD3), which was found to have demethylation activity 





6.4 Context-specific mode of NF-κB pathway regulation by EZH2 
and its Clinical Implications 
 
We have demonstrated that in a cellular context characterized by presence of RelB 
and absence of ER, EZH2 could positively regulate NF-κB target genes. Conversely, in the 
presence of ER and absence of RelB, EZH2 could collaborate with ER to suppress NF-κB 
target genes.  Therefore, the counterbalance between ER and RelB expression in ER positive 
and ER negative breast cancer cells appears to be crucial in determining EZH2 role as a 
repressor or an activator of NF-κB targets in breast cancer cells.   
Interestingly, it was reported that tamoxifen (ER antagonist) response is more 
favourable in tumors with low EZH2 expression (Reijm et al., 2011). If we apply our 
proposed model in this clinical observation, it is possible that in response to long-term 
inhibition of ER by tamoxifen, RelB could be upregulated, leading to the constitutive 
activation of NF-κB target genes by RelA/RelB when EZH2 is also expressed at a higher 
level. Hence, tamoxifen treatment could be beneficial to those patients with lower EZH2 
expression as they exhibit lower propensity towards the EZH2-mediated constitutive 
activation loop of NF-κB pathway. 
In addition, it was observed that patients with low EZH2 expression in inflammatory 
breast cancer would confer better prognosis (Gong et al., 2011). Albeit EZH2 was implicated 
in the activation of NF-κB through suppressing DAB3IP, it could not explain its role in 
constitutive activation of NF-κB in inflammatory breast cancer. Alternatively, by applying 
our proposed model in this scenario, this observation may imply that high expression of 
EZH2 in inflammatory breast cancer could result in constitutive activation of NF-κB 






6.5 EZH2 acts more than a methyltransferase in oncogenic 
progression 
 
In 1990s, EZH2 was first discovered to play a critical role in maintaining stem cell 
pluripotency by suppressing the expression of differentiation genes (Laible et al., 1997). In 
2000s, research on EZH2 was altered to focus on the role of PRC2 in promoting 
tumorigenesis of multiple types of malignancies including leukemia, prostate and breast 
cancers (Sauvageau and Sauvageau, 2010). The oncogenic roles of EZH2 are mainly 
attributed to its transcriptional repression activity on various tumour suppressor genes 
including CDKN1C, CDH1, and Bim (Cao et al., 2008; Wu et al., 2010; Yang et al., 2009a). 
This gene silencing function of EZH2 is dependent on its enzymatic activity in catalyzing the 
trimethylation at Histone 3 Lysine 27 (H3K27me3) (Cao and Zhang, 2004a). Studies have 
demonstrated that in order for EZH2 to function as a histone methyltransferase, it has to 
associate physically with suppressor of zeste 12 (SuZ12) and embryonic ectoderm 
development (EED) to form the core complex of Polycomb Repression Complex 2 (PRC2) 
(Cao and Zhang, 2004b). 
Intriguingly, despite of the frequent overexpression of EZH2 in a range of 
malignancies, its interacting partners of the core PRC2 complex, in particularly EED was not 
found to be substantially overexpressed in cancers (Chase and Cross, 2011). On the contrary, 
homozygous hypomorphic or heterozygous null mutations of EED in mice was demonstrated 
to promote relapse of lymphoma (Sauvageau and Sauvageau, 2010). One of the possibilities is 
that PRC2 complex could function as a tumor suppressor. However, this phenomenon was not 
demonstrated thus far. Another possibility is that in the absence of EED, the stoichiometry of 
PRC2 complex would be imbalanced and resulting in the excessive EZH2 to function 
independently of PRC2 complex. This gain of function of EZH2 independent of PRC2 would 
confer oncogenic propensity. Recent studies have discovered recurrent missense or nonsense 





al., 2010; Makishima et al., 2010; Score et al., 2012). Such mutations were also shown to be 
associated with poor prognosis. Again, it is possible that the catalytic incompetent EZH2 
mutant could also exhibit gain-of-function activity and confer oncogenesis. This could be 
exemplified by Shi et al. and our study demonstrating that EZH2 could serve as a 
transcriptional activator of two oncogenic signaling pathways, ER/β-catenin and NF-κB, 
which would further contribute to tumor progression (Lee et al., 2011; Shi et al., 2007). 
Although the transcriptional repressive function of EZH2 was long known to be 
responsible for tumor progression, the critical tumor stage at which H3K27 trimethylation 
contributes to oncogenesis is largely unknown. A recent study reported that H3K27 
trimethylation occurs as an early epigenetic event in hepatocellular carcinogenesis by 
silencing p16INK4a, and this repressive mark would then be replaced by H3K9 dimethylation 
during the later development (Yao et al., 2010). An independent study showed that H3K9 
dimethylation preceeds DNA methylation and histone deacetylation on p16INK4a locus and the 
latter epigenetic marks serve to maintain the gene silencing. Besides, PRC2 complex is 
known to recruit histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) 
during the course of transcriptional repression (Bachman et al., 2003). Paradoxically, 
researchers have found DNA methylation to be independent of H3K27me3 and the overlap 
between DNA methylated and H3K27 trimethylated regions is modest (Kondo et al., 2008). 
One possible explanation is that when PRC2 catalyzes H3K27me3 during early stages of 
oncogenesis, the complex would recruit DNMTs that would catalyze DNA methylation for 
long term suppression. While the H3K27me3 marks would subsequently being erased by 
other histone modifying enzymes over time. These findings suggest that epigenetic 
modification appears to be a dynamic event during oncogenic progression. PRC2-mediated 
H3K27me3 could be an early event of tumor progression and this suppressive mark could be 
subsequently substituted by other stable epigenetic repressive mechanisms (e.g., DNA 





Given that PRC2-mediated transcriptional repression could potentially be replaced by 
other long term repressive mechanisms, would this activity still be substantial and essential as 
the tumor progresses? Wei et al demonstrated by immunohistochemical staining showing that 
H3K27me3 level decreases as the tumor develops to the more advance stage (Wei et al., 
2008). In this study, it was shown that breast, ovarian, and pancreatic tumors with larger size, 
higher tumor grade, and more lymph node metastasis tend to have lower H3K27me3 level, 
albeit higher level of EZH2 was found to be associated with the more advance tumors. 
Patients with lower H3K27me3 and higher EZH2 level were therefore associated with poor 
prognosis. This seems to suggest that although EZH2-mediated H3K27me3 modification 
became less substantial as the tumor progressed, high level of EZH2 remained essential in 
advance tumors. This implies that EZH2 could exert oncogenic influence through means other 
than its H3K27-trimethylating catalytic activity for promoting cancer progression. We have 
reported that EZH2 could act as a transcriptional activator independent of its 
methyltransferase activity, promoting NF-κB signaling in the more aggressive ER-negative 
breast cancer and confers poor clinical outcome. In agreement with our findings, Wei et al 
also reported that EZH2 is more overexpressed in ER-negative breast cancer although 







6.6 Significance of Study 
 
Both EZH2 and NF- B contribute to aggressive breast cancer, yet existence of a 
functional crosstalk between these two factors in breast cancer is still unclear. Here, we 
uncover an unexpected role of EZH2 in inducing NF-κB target gene expression in ER-
negative basal-like breast cancer cells.  This function of EZH2 is independent of its histone 
methyltransferase activity but requires the physical interaction with RelA/RelB. Intriguingly, 
EZH2 acts oppositely in repressing NF-κB targets in ER-positive luminal breast cancer cells 
by interacting with ER and directing repressive H3K27 trimethylation. Thus, EZH2 function 
as a double-facet molecule in breast cancers, functioning either as a transcriptional activator 
or repressor of NF-κB targets, in a cell context-dependent manner.  
Targeting of NF-κB in cancer therapeutics has been jeopardized by its essential roles 
in maintaining normal physiological homeostasis (Baud and Karin, 2009). Hence, it would be 
beneficial to target certain pathways that are specifically activated in cancers. Our findings of 
EZH2 transactivation function on NF-κB pathway could be one such example. Our data 
suggest that this transactivation property require at least two crucial factors: (i) higher 
expression of RelB and (ii) aberrant overexpression of EZH2. These criteria should not be 
fulfilled in healthy cells under normal circumstances, but were observed frequently in 
aggressive ER-negative breast cancer cells. Hence, drugs targeting this oncogenic complex 
would be specific to this subtype of breast cancer. 
In the development of EZH2 targeted therapy, research effort was focused on small 
molecule inhibitors of EZH2 enzymatic activity. 3-Deazaneplanocin A (DZNep) is one of S-
adenosylhomocysteine (AdoHcy) hydrolase inhibitors that was shown to be able to deplete 
PRC2 complex and hence exert antitumor activity in various types of cancers (Tan et al., 
2007). However, reports have shown that the specificity of DZNep is suboptimal and it could 
cause a reduction of global histone methylation (Miranda et al., 2009). This indicates the need 





methyltransferase activity in promoting aggressive phenotypes in ER-negative breast cancer 
cells, the effectiveness of the small molecule inhibitors targeting EZH2 methyltransferase 
activity could be limited. Therefore, novel targeting approaches such as interfering with 
EZH2 transactivation function may be considered for the treatment of advance tumors that 
have high EZH2 level but low H3K27me3. It is worth to mention that patient stratification 
would be a necessary procedure prior to implementing these EZH2 targeted strategies. This is 
especially so as EZH2 could repress NF-κB signalling in ER-positive breast cancer cells, 
inhibiting its methyltransferase activity in this breast cancer subtype may result in undesirable 
activation of NF-κB network. The 12 signature genes identified from the breast cancer cell 
line panel in this study could potentially be adopted for predicting BLBC patient subsets that 
would respond to inhibitors targeting EZH2-NF-κB interactions.  





6.7 Future Prospects 
 
In this study, we have detected the physical interaction between EZH2, RelA, and 
RelB, which enhanced the aggressiveness of BLBC cells. The next immediate question would 
be the identification of protein domains in EZH2, RelA, and RelB responsible for the 
interactions that stabilized this complex. This is a necessary experiment before moving on to 
the development of interfering peptide inhibitors specific to the EZH2-NF-κB interactions. 
Thus far, most peptide inhibitors that were approved in clinical trials usually target cell-
surface receptor as a result of serious challenges associated with peptide delivery into the 
cells. Given that many natural products were found to have activity interfering protein-protein 
interactions (as mentioned in section 1.3.2.3), screening of natural products could be a good 
starting point to search for compounds interfering EZH2/RelA/RelB interactions. 
Based on our data, we found that EZH2 could also function as a corepressor of ER in 
ER-positive breast cancer cells to suppress NF-κB target genes. It would be interesting to 
investigate if such transcriptional collaboration with EZH2 could also be observed for other 
hormone nuclear receptor in other types of cancers, for instance ovarian and prostate cancers. 
Indeed, recent reports have demonstrated that EZH2 could act as a corepressor of AR in 
prostate cancer (Chng et al., 2012; Yu et al., 2010). Therefore, it might be worthwhile to 
establish the role of EZH2 with respect to different types of cancers so as to assess the 






























Appendix 1: Quantitative Realtime PCR of cDNA primer sequences: 
Gene  Forward primer  Reverse primer 
18S  CGAACGTCTGCCCTATCAACTT  ACCCGTGGTCACCATGGTA 
IL8  GAGTGATTGAGAGTGGACCACACT  AGACAGAGCTCTCTTCCATCAGAAA 
IL6  GTACATCCTCGACGGCATCTC  GCTGCTTTCACACATGTTACTCTTG 
TNFα  CCCAGGCAGTCAGATCATCTTC  GGTTTGCTACAACATGGGCTACA 







Appendix 2: Quantitative Realtime PCR of ChIP primer sequences: 
Gene MB231 MCF7 Forward primer Reverse primer 
IL6 P1 - TAGGTGCTACCTCTGGGAAAAGG AGGGCATGCAGGGAAAAGT 
  P2 P1 AGGCGGGTCCTGAAATGTT GACCTCTGTTGGGCATTTACTCA 
  P3 P2 TGGAGACGCCTTGAAGTAACTG GTGAGCGGCTGTTGTAGAACTG 
  P4 P3 GTCTGAGGCTCATTCTGCCC  AGAGCTTCTCTTTCGTTCCCG  
  P5 P4 CCAGTACCCCCAGGAGAAGAT AAGAGGTGAGTGGCTGTCTGTGT 
  - P5 AACTCAATGGCTAGGATTCCTCAA CCACTTTGGTGGGCTCTGA 
TNF P1 P1 AAATCAGTCAGTGGCCCAGAA CCCTCACACTCCCCATCCT 
  P2 P2 CGCCACATCCCCTGACA CGTGGGTCAGTATGTGAGAGGAA 
  P3 P3 AGAGCTGTTGAATGCCTGGAA CTGGCCTGCGCTCTTAGC 
  P4 P4 CTCGAACCCCGAGTGACAA AAGACACATCCTCAGAGCTCTTACC 
  P5 P5 TGCTCCTCACCCACACCAT GGAGGTTGACCTTGGTCTGGTA 
IL8 P1 P1 GCCACCTTTTTATGATTTGTTGAA CCTCTGAGGACCCATGATCACT 
  P2 P2 GTGCTGTTCTCTTTCATCTTCCTCTA CAGTTGGAGCAAGGCATTGA 
  P3 P3 TGGGCCATCAGTTGCAAA ACTTATGCACCCTCATCTTTTCATT 
  P4 P4 AAACCACCGGAAGGAACCA CACGGCCAGCTTGGAAGT 
  P5 P5 ACTAACTGAGGTCAAGGGCTAGGA GAGACTATGGAAGGCATCATGTTTC 
BIRC3 P1 P1 AATGGGCAAGGGAATGCA GCAGGCCTTACACATTTTTGATT 
  P2 P2 GGGAAATATGGCAGTGCAATTAG TTCTGAGTTGCAGTGCCATTCT 
  P3 P3 TCCCCGAGTGGGTTTGC AGCGGTAATAACCACACACACTTC 
  P4 P4 TTGTGAAGTTGTGGCATTTTGAT CCTGCAAAGGCCCAGTGAT 
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